Studies on Synthetic Drugs by Vaghasia, Shailesh J.
          Saurashtra University 
     Re – Accredited Grade ‘B’ by NAAC 










Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author. 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the author, title, 




















FOR THE DEGREE OF
Doctor of Philosophy
IN
THE FACULTY OF SCIENCE (CHEMISTRY)
BY
Mr. SHAILESH J. VAGHASIA
UNDER THE GUIDANCE
OF
Dr. V. H. Shah (M.Sc. Ph.D. FIC)
DEPARTMENT OF CHEMISTRY
(DST-Funded & UGC-SAP Sponsored)
SAURASHTRA UNIVERSITY
(**** By NAAC)





1S t u d i e s  o n  s y n t h e t i c  d r u g s i n d e x
CONTENTS
       PAGE NO.
SYNOPSIS . . . . . . . .   01
STUDIES ON SYNTHETIC DRUGS
INTRODUCTION .. .. .. ..   11
( A ) STUDIES ON PYRIMIDINE DERIVATIVES
Introduction .. .. .. ..   19
PART : A STUDIES ON PYRAZOLO[3,4-d]PYRIMIDINES
SECTION - I : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-
ARYL-6-MERCAPT OMETHYL-4,5-DIHYDRO-1H-PYRAZOLO-
[3,4-d]PYRIMIDINES.
Introduction and spectral studies .. .. .. ..   29
Experimental .. .. .. ..   35
Data of in vitro evaluation of antimicrobial activity .. .. ..   39
SECTION - II : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-
ARYL-6-METHYLSULFONYL-1H-PYRAZOLO[3,4-d]PYRIMIDINES.
Introduction and spectral studies .. .. .. ..   42
Experimental .. .. .. ..   48
Data of in vitro evaluation of antimicrobial activity .. .. ..   50
SECTION - III : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-
ARYL-6-HYRAZINO-4,5-DIHYDRO-1H-PYRAZOLO[3,4-d]PYRIMIDINES.
Introduction and spectral studies .. .. .. ..   53
Experimental .. .. .. ..   59
Data of in vitro evaluation of antimicrobial activity .. .. ..   61
SECTION - IV : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-
ARYL-6-(2,4-DINITROPHENYL)THIO-4,5-DIHYDRO-1H-PYRAZOLO
[3,4-d]PYRIMIDINES .
Introduction and spectral studies .. .. .. ..   64
Experimental .. .. .. ..   70
2S t u d i e s  o n  s y n t h e t i c  d r u g s i n d e x
       PAGE NO.
Data of in vitro evaluation of antimicrobial activity .. .. ..   72
SECTION - V : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-
ARYL-6-MERCAPTOMETHYL-1-PHENYL-4,5-DIHYDRO-1H- PYRA-
ZOLO[3,4-d]PYRIMIDINES.
Introduction and spectral studies .. .. .. ..   75
Experimental .. .. .. ..   81
Data of in vitro evaluation of antimicrobial activity .. .. ..   83
SECTION - VI : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-
ARYL-6-METHYLSULFONYL-1-N-PHENYLPYRAZOLO[3,4-d]PYRIMI-
DINES.
Introduction and spectral studies .. .. .. ..   86
Experimental .. .. .. ..   92
Data of in vitro evaluation of antimicrobial activity .. .. ..   94
SECTION - VII : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-
ARYL-6-HYRAZINO-1N-PHENYL-4,5-DIHYDROPYRAZOLO[3,4-d]-
PYRIMIDINES.
Introduction and spectral studies .. .. .. ..   97
Experimental .. .. .. ..  103
Data of in vitro evaluation of antimicrobial activity .. .. ..  105
SECTION - VIII : PREPARATION AND BIOLOGICAL EVALUATION OF 3- METHYL-4-
ARYL-6-(2’,4’-DINITROPHENYL)THIO-4,5-DIHYDRO-1H-PYRAZOLO-
[3,4-d]PYRIMIDINES .
Introduction and spectral studies .. .. .. ..  108
Experimental .. .. .. ..  114
Data of in vitro evaluation of antimicrobial activity .. .. ..  116
SECTION- IX : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL- 4-
(1’-N-PHENYL-3’-ARYL-1H-PYRAZOL-4’-YL)-6-MERCAPTO-4,5-
DIHYDRO-1H-PYRAZOLO[3,4-d]PYRIMIDINES.
3S t u d i e s  o n  s y n t h e t i c  d r u g s i n d e x
       PAGE NO.
Introduction and spectral studies .. .. .. ..  119
Experimental .. .. .. ..  125
Data of in vitro evaluation of antimicrobial activity .. .. ..  127
SECTION- X : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL- 4-
(1’-N-PHENYL-3’-ARYL-1H-PYRAZOL-4’-YL)-6-MERCAPTO-4,5-
DIHYDRO-1H-PYRAZOLO[3,4-d]PYRIMIDINES.
Introduction and spectral studies .. .. .. ..  130
Experimental .. .. .. ..  136
Data of in vitro evaluation of antimicrobial activity .. .. ..  138
SECTION- XI : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-
(1’-N-PHENYL-3’-ARYL-1H-PYRAZOL-4’-YL)-6-AMINO-4,5-DIHYDRO-
1H-PYRAZOLO[3,4-d]PYRIMIDINES.
Introduction and spectral studies .. .. .. ..  141
Experimental .. .. .. ..  147
Data of in vitro evaluation of antimicrobial activity .. .. ..  149
References .. .. .. ..  152
( B ) STUDIES ON QUINAZOLINE DERIVATIVES
Introduction .. .. .. ..  156
PART : I STUDIES ON QUINAZOLINE
SECTION - I : PREPARATION AND BIOLOGICAL EVALUATION OF 5,5,7-TRIMETHYL-
4-(1’-N-PHENYL-3’-ARYLPYRAZOL-4’-YL)-2-HYDROXY-3,4,5,6-TETRA-
HYDROQUINAZOLINES.
Introduction and spectral studies .. .. .. ..  163
Experimental .. .. .. ..  169
Data of in vitro evaluation of antimicrobial activity .. .. ..  171
SECTION - II : PREPARATION AND BIOLOGICAL EVALUATION OF 5,5,7-TRIMETHYL-
4-(1’-N-PHENYL-3’-ARYLPYRAZOL-4’-YL)-2-MERCAPTO-3,4,5,6-TETRA-
HYDROQUINAZOLINES.
4S t u d i e s  o n  s y n t h e t i c  d r u g s i n d e x
       PAGE NO.
Introduction and spectral studies .. .. .. ..  174
Experimental .. .. .. ..  180
Data of in vitro evaluation of antimicrobial activity .. .. ..  182
SECTION - III : PREPARATION AND BIOLOGICAL EVALUATION OF 5,5,7-TRIMETHYL-
4-(1’-N-PHENYL-3’-ARYLPYRAZOL-4’-YL)-2-AMINO-3,4,5,6-TETRA-
HYDROQUINAZOLINES.
Introduction and spectral studies .. .. .. ..  185
Experimental .. .. .. ..  191
Data of in vitro evaluation of antimicrobial activity .. .. ..  193
SECTION- IV : PREPARATION AND BIOLOGICAL EVALUATION OF 4-ARYL-5,5-
DIMETHYL-7-(2’-PIPERIDIN-1’-YL-ETHYL)-2-HYDROXY-3,4,5,6-
TETRAHYDROQUINAZOLINES.
Introduction and spectral studies .. .. .. ..  196
Experimental .. .. .. ..  202
Data of in vitro evaluation of antimicrobial activity .. .. ..  204
SECTION- V : PREPARATION AND BIOLOGICAL EVALUATION OF 4-ARYL-5,5-
DIMETHYL-7-(2’-PIPERIDIN-1’-YL-ETHYL)-2-MERCAPTO-3,4,5,6-
TETRAHYDROQUINAZOLINES.
Introduction and spectral studies .. .. .. ..  208
Experimental .. .. .. ..  214
Data of in vitro evaluation of antimicrobial activity .. .. ..  216
References .. .. .. ..  219
( C ) STUDIES ON PYRAZOLO DERIVATIVES
Introduction .. .. .. ..  221
PART : I STUDIES ON PYRAZOLINES
SECTION - I : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-5-
N-AROYL-7-AMINOPYRAZOLO[3’,4’:4,5]THIENO[2,3-c]PYRAZOLES.
Introduction and spectral studies .. .. .. ..  226
Experimental .. .. .. ..  232
Data of in vitro evaluation of antimicrobial activity .. .. ..  234
5S t u d i e s  o n  s y n t h e t i c  d r u g s i n d e x
       PAGE NO.
SECTION - II : PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-6-
ARYL-1,5,6,7-TETRAHYDROPYRAZOLO[3’,4’:4,5]THIENO[2,3-d ]
PYRIMIDIN-8-ONES.
Introduction and spectral studies .. .. .. ..  237
Experimental .. .. .. ..  243
Data of in vitro evaluation of antimicrobial activity .. .. ..  245
SECTION - III : PREPARATION AND BIOLOGICAL EVALUATION OF 3,6-DIMETHYL-
6-ARYL-1,5,6,7-DIHYDRO-1H-PYRAZOLO[3’,4’:4,5]THIENO[2,3-d]
PYRIMIDIN-8-ONES.
Introduction and spectral studies .. .. .. ..  248
Experimental .. .. .. ..  254
Data of in vitro evaluation of antimicrobial activity .. .. ..  256
References .. .. .. ..  259
S Y N O P S I S 1
            A brief summary of the work to be incorporated in the thesis  entitled
“STUDIES ON SYNTHETIC DRUGS’’ has been summarized as under.
( A )   STUDIES ON  PYRIMIDINE DERIVATIVES
( B )   STUDIES ON QUINAZOLINE DERIVATIVES
( C )   STUDIES ON PYRAZOLE DERIVATIVES
( A )   STUDIES ON  PYRIMIDINE DERIVATIVES
PART - I : STUDIES ON  PYRAZOLO[3,4-d]PYRIMIDINES
Pyrazolo [3,4-d] pyrimidines represents one of the most active classes of
compounds possessing a wide spectrum of b io logical  act iv i t ies v iz.
anticancer,anti-HIV,antitumor,antiviral,antiparasitic etc.Pyrazolo[3,4-d]pyrimidines
can be used as a chemotherapeutic agent against neurosfora. It was thought
worthwhile to synthesize some newer pyrazolo[3,4-d]pyrimidines and its
derivatives which can be summarized as under.
SECTION - I   : Preparation and biological evaluation of 3-Methyl-4-aryl










     (a) R=Aryl
 Pyrazolo[3,4-d]pyrimidines (a) have been prepared by the condensation of
3-methyl-4-aryl-6-mercapto-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines with dimethyl
sulphate in the presence of base.
SECTION - II : Preparation and biological evaluation of 3-Methyl-4-aryl
-6-methylsulfonyl-1H-pyrazolo[3,4-d]pyrimidines.












     (b) R=Aryl
Pyrazolo[3,4-d]pyrimidines (b) have been prepared by the condensation
of 3-methyl-4-aryl-6-methylthio-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines with
hydrogen peroxide and gla. acetic acid.
                                                                                                       
SECTION - III : Preparation and biological evaluation of 3-Methyl-4-aryl-










   (c) R=Aryl
Pyrazolo[3,4-d]pyrimidines (c) have been prepared by the condensation of
3-methyl-4-aryl-6-methylthio-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines with
hydrazine hydrate.
SECTION - IV : Preparation and biological evaluation of 3-Methyl-4-aryl-
      6-(2’,4’-dinitrophenyl)thio-4,5-dihydro-1H-pyrazolo[3,4-d]-
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Pyrazolo[3,4-d]pyrimidines (d) have been prepared by the condensation of
3-methyl-4-aryl-6-mercapto-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines with
1-chloro-2,4-dinitrobenzene.
SECTION - V :    Preparation and biological evaluation of 3-Methyl-4-aryl-
        6-methylthio-1-N-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]-










   (e) R=Aryl
Pyrazolo[3,4-d]pyrimidines (e) have been prepared by the condensation
of 3-methyl-4aryl-6-mercapto-1-N-phenyl-4,5-dihydro-1H-pyrazolo [3,4-d]pyrimidines
with dimethyl sulphate in presence of the base.
SECTION - VI :   Preparation and biological evaluation of 3-Methyl-4-aryl-












    (f) R=Aryl
Pyrazolo[3,4-d]pyrimidines (f) have been prepared by the 3-methyl-4-aryl-
1-N-phenyl-6-methylthio-4,5-dihydro-1H-pyrazolo[3,4-d] pyrimidines with hydrogen
peroxide and gla.acetic acid.
SECTION-VII :    Preparation and biological evaluation of 3-Methyl-4-aryl-
        6-hydrazino-1-N-phenyl-4,5-dihydro-1H-pyrazolo[3,4-d]-
        pyrimidines.










   (g) R=Aryl
Pyrazolo[3,4-d]pyrimidines (g) have been prepared by the 3-methyl-4-aryl-1-N-
phenyl-6-methylthio-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines with hydrazine hydrate.
SECTION - VIII :  Preparation and biological evaluation of 3-Methyl-4-aryl-
         6-(2’,4’-dinitrophenyl)thio-1-N-phenyl-4,5-dihydro -1H-











   (h) R=Aryl
Pyrazolo[3,4-d]pyrimidines (h) have been prepared by the condensation
of 3-methyl-4-aryl-1-N-phenyl-6-mercapto-4,5-dihydro-1H-pyrazolo[3,4-d]
pyrimidines with 1-chloro-2,4-dinitrobenzene.
SECTION - IX :    Preparation and biological evaluation of 3-Methyl-4-(1’-N-
         phenyl-3’-arylpyrazol-4’-yl)-6-hydroxy-4,5-dihydro-1H-
         pyrazolo[3,4-d]pyrimidines.
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 (i)                        R=Aryl
Pyrimidines (i) have been synthesized by the condensation of different 3-
aryl-1-N-phenyl-1H-pyrazol-4-carbaldehydes, 5-methyl-2,4-dihydro-3H-pyrazol-3-
one and urea.
SECTION - X :       Preparation and biological evaluation of 3-Methyl-4-(1’-N-
         phenyl-3’-aryl pyrazol- 4’-yl)-6-mercapto-4,5-dihydro-1H-










Pyrazolo[3,4-d]Pyrimidines (j) have been synthesized by the condensation
of different 3-aryl-1-N-phenyl-1H-pyrazole-4-carbaldehydes, 5-methyl-2,4-dihydro-
3H-pyrazol-3-one and thiourea.
SECTION - XI :    Preparation and biological evaluation of 3-Methyl-4-(1’-N-
         phenyl-3’-arylpyrazol-4’-yl)-6-amino-4,5-dihydro-1H-pyrazolo
         [3,4-d]pyrimidines.










Pyrazolo [3,4-d] pyrimidines (k) have been synthesized by the condensation
of different 3-aryl-1-N-phenyl-1H-pyrazole-4-carbaldehydes, 5-methyl-2,4-dihydro-
3H-pyrazol-3-one and guanidine hydrochloride.
 ( B )   STUDIES ON  QUINAZOLINES
PART - II : STUDIES ON  QUINAZOLINES
Quinazolines play a vital role owing to their wide range of biological activity
viz.antiviral,antifungal,antitubercular,anticonvulsant, anticancer and anti AIDS, etc.
In view of these valid observations, it was contemplated to synthesize some newer
quinazolines  possessing better drug potential with least side effect, which can
be summarized as under.
SECTION - I : Preparation and biological evaluation of 5,5,7-Trimethyl
4-(1’-N-phenyl-3’-arylpyrazol-4’-yl)-2-hydroxy-3,4,5,6-tetrahydro
quinazolines.







   (l) R=Aryl
Quinazolines (l) have been prepared by the cyclocondensation of different
3-aryl-1-N-phenyl-1H-pyrazole-4-carbaldehydes,3,5,5-trimethylcyclohex-2-en-1-
one and urea.










  (m) R=Aryl
Quinazolines (m) have been prepared by the cyclocondensation of different
3-aryl-1-N-phenyl-1H-pyrazole-4-carbaldehydes,3,5,5-trimethylcyclohex-2-en-1-
one and thiourea.
SECTION - III : Preparation and biological evaluation of 5,5,7-Trimethyl-
4-(1’-N-phenyl-3’-arylpyrazol-4’-yl)-2-amino-3,4,5,6-
tetrahydro quinazolines.








  (n) R=Aryl
Quinazolines (n) have been prepared by the cyclocondensation of different
3-aryl-1-N-phenyl-1H-pyrazol-4-carbaldehydes,3,5,5-trimethylcyclohex-2-en-1-one
and guanidine hydrochloride.
SECTION - IV : Preparation and biological evaluation of 4-Aryl-5,5-dimethyl-
       7-(2’-piperidin-1’-yl-ethyl)-2-hydroxy-3,4,5,6-tetrahydro-









( o ) R=Aryl
        Quinazolines (o) have been prepared by the condensation of 4-aryl-2-hydroxy
5,5,7-trimethyl-3,4,5,6-tetrahydroquinazolines,piperidine and formaldehyde.
SECTION - V :  Preparation and  biological  evaluation 4-Aryl-5,5-dimethyl-
       7-(2’-piperidin-1’-yl-ethyl)-2-mercapto-3,4,5,6-tetrahydro-
       quinazolines.









                                                                  (p) R=Aryl
Quinazolines (p) have been prepared by the condensation of 4-aryl-2-
mercapto-5,5,7-tr imethyl-3,4,5,6-tetrahydroquinazolines, piperidine and
formaldehyde.
( C )   STUDIES ON PYRAZOLE DERIVATIVES
PART - III : STUDIES ON PYRAZOLINE DERIVATIVES
Pyrazoles are one of the most active class of compounds possessing
diverse biological activity viz. anticancer,anti-HIV,antitumor, diuretic,antipyretic
and antimicrobial.Prompted by above facts ,some newer pyrazoles have been
prepared as under.













 Pyrazolo[3’,4’:4,5]thieno[2,3-c]pyrazoles (q) have been prepared by the
cyclocondensation of 5-amino-6-cyano-3-methyl-1H-thieno[3,2-c]pyrazole and
different acid hydrazides in the presence of gla.acetic acid.
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Pyrazolo[3’,4’:4,5]thieno[2,3-d]pyrimidin-8-ones  (r) have been prepared by
the cyclocondensation of 3-methyl-5-amino-6-carboxamido-1H-thieno[3,2-c]
pyrazole and different substituted aromatic aldehydes in the presence of con.
sulfuric acid and gla. acetic acid.















Pyrazolo[3’,4’:4,5]thieno[2,3-d]pyridin-8-ones (s) have been prepared by
the cyclocondensation of 3-methyl-5-amino-6-carboxamido-1H-thieno[3,2-c]
pyrazole and  different substituted acetophenones in the presence of con.sulfuric
acid and gla. acetic acid.
Pure organic compounds have been screened for their in vitro therapeutic
assay like antibacterial activities towards S. pyogens MTCC-442 and S. aureus
MTCC-96  (Gram positive) and E.coli MTCC-443 and B.subtilis MTCC-441
(Gram negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282 and Candida albicans MTCC-227 at different concentrations
(Minimum Inhibitory  Concentration). The biological activities of synthesized
compounds have been compared with standard drugs.
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STUDIES ON SYNTHETIC DRUGS
(A) Drug
The word drug is derived from the French word “drogue” which means
‘a dry herb’. It is the single active chemical entity present in a medicine that is
used for diagnosis, prevention, treatment / cure of a disease. This disease
oriented definition of drug does not include contraceptives or use of drugs for
improvement of health. According to “WHO” a drug may be defined as “Any
substance or product which is used or intended to be used for modifying or
exploring physiological system as pathological status for the benefit of the
recipient”.
(B) Pharmacology
Pharmacology is the science of drugs. In a broad sense, it deals with
interaction of exogenously administered chemical molecules (drugs) with living
system. It encompasses all aspects of knowledge about drugs, but most
importantly those that are relevant to effective and safe use for medicinal
purposes. For thousands of years most drugs were crude natural products of
unknown composition and limited efficiency. Only the over effects of these
substances on the body were rather imprecisely known, but how the same were
produced was entirely unknown. Over the past 100 years or so, drugs have been
purified, chemically characterized and a vast variety of highly potent and
select ive new drugs has been developed. The two main div is ions of
pharmacology are pharmacodynamics and pharmacokinetics.
(a) Pharmacodynamics :  It is derived from the Greek word “dynamic” means
power. What the drugs does to the body ? This includes physiological
and biochemical  ef fects of  drugs and their  mechanism of act ion at
macromolecular / sub cellular organ systems.
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(b) Pharmacokinetics :  It is derived from the Greek word ‘Kinesis’ means
movement. What the body does to the drug ? This refers to movements of
the drug in and alternation of the drug by the body; includes absorption,
distr ibut ion, binding /  local izat ion /  storage, biotransformation and
excretion of the drug.
Some other important aspects of pharmacology are given as under :
* Pharmacotherapeut ics  :  I t  i s  the  app l i ca t ion  o f  pharmaco-
dynamic  information together with knowledge of the disease for its
prevention, mitigation or cure.
* Clinical  Pharmacology  :  I t  is  the scient i f ic  study of  drug in man.
It  inc ludes pharmacodynamic and pharmacokinet ic  invest igat ion
i n healthy volunteers and in patients; evaluation of efficiency and safety
o f  d rugs  and  compara t i ve  t r ia l s  w i th  o ther  fo rms o f  t rea tments ;
surveillance of patterns of drug uses, adverse effects, etc.
* Chemotherapy : It is the treatment of systemic infection / malignancy
with speci f ic  drugs that  have select ive toxic i ty  for  the infect ing
organism / malignant cell with less effect on the host cells.
n  Drugs in general, can thus be divided into :
* Pharmacodynamic agents : These are chemical substances designed
to have pharmacodynamic effect in the recipient.
* Chemotherapeutic agents : These are chemical substances desi gned for
the treatment of infectious diseases or by the proliferation of malignant cells .
(c) Essential Drug Concept: The ‘WHO’ has defined Essential Drugs as
“those that satisfy the healthcare needs of majority of the population; they
should therefore be available at all times in adequate amounts and in
appropriate dosage form”.
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It has been realized that only a handful of drugs out of the multitude
available can meet the health needs of majority of the people in any country, and
that may be well tested and cheaper drugs are equally (or more) efficient and
safe as their newer more expensive congeners. For optimum utilization of
resources, governments (specially in developing countries) should concentrate
on these drugs by identifying them as Essential Drugs. The “WHO” has laid down
criteria guide selection of an essential drug :
(I) Adequate data on its efficiency and safety should be available from
          clinical studies.
(II) It should be available in a form in which quality, including bioavailability,
and stability on storage can be assured.
(III) Its choice should depend upon pattern of prevalent diseases; availability
o f  fac i l i t ies  and t ra ined personnel ;  f inanc ia l  resources;  genet ic ,
demographic and environmental factors.
(IV) In case of two or more similar drugs, choice should be made on the basis
          of their relative efficiency, safety, quality, price, availability and cost
          benefit ratio should be a major consideration.
(V) Choice may also be influenced by comparative pharmacokinetic properties
and local facilities for manufacture and storage.
(VI) Most essential drug should be single compound. Fixed ratio combination
products should be included only when dosage of each ingredient meets
the requirements of a defined population group, and when the combination
has a proven advantage.
(VII) Selection of essential drug should be a continuous process which should
take into account the changing priorities for public health action, epide-
miological condition as well as availability of better drugs/ formulations and
progress in pharmacological knowledge.
(C)  Drug Development
Many natural products by trial and error, came into practise for combating
human ailments existent during early human observation. With the advent of
modern scientific approach, various plant medicines came under chemical
scrutiny, ultimately leading to the isolation of active principles since early.
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Such compounds either in extract form or in pure form became a part of
pharmacopoeias. For instance, though the Chinese drug, Mauhang was in use
for over 5000 years for the treatment of various types of fever and respiratory
ailments, its active principle, Ephidrine was isolated in 1887. In 1925 chemical
investigations followed by pharmacological evaluation led this compound into the
modern medicine. Similarly during this period, urea stibamine was introduced as
the first drug in 1920 for the treatment of Kala-azar. In 1930, De Rauwolfia
preparation were first employed for sedative and hypotensive properties.
A drug is a substance having abnormal effect on certain body functions eg.
Strychnine stimulates the action of heart and aspirin retards its action. Since both
of them effects abnormally, the two substances are known as drugs. Chemical
sciences contributed extensively new discoveries leading to useful drugs since
after 1930. The modern concept of drug discovery started in 1933 by Gerhand
Domagk with his finding of “Prontosil Red” , a compound responsible for the
antibacterial activity. The advent of sulphonamides  drew the attention for the
different activities of various chemicals for bacterial and human cells, this impor-
tant factor prompted Florey and Chain in 1939 to investigate penicillin  which
was discovered ten years earlier by Alexander Fleming. The spectacular
chemotherapeut ical  propert ies of  penic i l l in and i ts dramatic war-t ime
development for the treatment of wounds made penicillin , a most commonly used
inexpensive drug.
           A large number of important drugs have been introduced during the period
of 1940 to 1980. This period is known as “Golden period” of new drug discovery.
Thus starting from 1933 - the first antibacterial drug prontosil  leading to various
sulpha drugs ; 1940 – penicillin  ; 1945 – chloroquine  – antimalarial ; 1950 –
Methyldopa  – anti-hypertensive;  1967 – chlorothiazine -diuretic ; 1958 - adr-
energic beta blockers coronary vasodilatory; 1960 - semi synthetic penicillin  -
ant ibacter ial ;  1965 - tr imethoprim -antimicrobial ;1967-  d isodium
chromoglycoate - antiallergic; 1972 - cimetidine H2 – antagonist; 1975
-verapamil- calciumantagonist and 1981 - captopril  - antihypertensive. There
are some specific examples representing new therapeuticagent  eg. Metormine glipizide-
anti diabetic.
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(D) Latest Drug Developments
The current interest in the creation of large, searchable libraries of
organic compounds has captured the imagination of organic chemists and the
drug discovery community. In numerous laboratories the Efforts are focused on
the introduction of chemical diversity, which have been recently reviewed and
pharmacologically interesting compounds have been identified from libraries of
widely different compositions.
Today, the chief source of agents for the cure, the mitigation or the
prevention of diseases are the organic compounds, natural or synthetic, together
with so-called organometallics. Such agents have their origin in a number of ways
(a) from naturally occurring materials - of both plant and animal origin, and (b)
from the isolation of organic compounds synthesized in laboratory whose struc-
tures are closely related to those of naturally occurring compounds for eg. atro-
pine, steroids, morphine, cocaine etc. that have been known to possess useful
medicinal properties.
The process of drug design is extensively driven by the instinct  and expe-
rience of pharmaceutical research scientists. It is often instructive to attempt to
“capture” these experiences by analyzing the historical record that are successful
drug design projects of the past. From this analysis, the inferences are drawn
which play an important role in shaping our  current and future projects. Towards
this region, we would like to analyse the structures of a large number of drugs -
the ultimate product of a successful drug design effort. Our goal for this is to  begin
to deconvolute this information in order to apply it to design of new drugs.
Different kinds of drugs are developed for different types of diseases viz.
which can be defined with their names of the modern drugs are as under.
(a) Anticancer drugs
The drugs, which stops the abnormal growth of cell tissues in human body,
are termed as anticancer drug. Vinblastin  and Busulphan are the novel
anticancer drugs.
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(b) Hepatoprotective drugs
Drugs, which gives vitality to liver and protects liver by giving immunity power
against antibodies, are termed as Hepatoprotective drug.
(c) Antimalarial drugs
Drugs, which kills the plasmodium causing malaria are called antimalarial
drug. Combination of Sulphamethoxazole  with Pyrimethamine is a novel
antimalarial drug.
(d)      Drug for meningitis
Drugs, which cures the inflammation of meningitis, are termed as
meningitis drugs Cifalexin  is a novel meningitis drug.
(e)      Drug for typhoid
Drugs, which kills the bacteria of Salmonella typhi causing typhoid are
known as typhoid drugs. A novel drug for typhoid is Ciprofloxacin .
(f)       Antidiabetic drugs
Drugs, which converts the excess glucose of blood into glycogen are termed
as antidiabetic drugs. Novel antidiabetic drugs are Metformin, Glipizide  and
Gliclazide.
(g) Antitubercular drugs
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus cures
lesions of pleural cavity. A novel antitubercular drug is Ethambutol.
(h) Antiasthamatic drugs
             Drugs, which prevents the attack of asthama and gives relax respiration
are called antiasthamatic drugs. Novel antiasthamatic drugs are Ethophylline,
Theophylline and Asmon.
(i) Antihypertensive drugs
            Drugs, which normalizes the blood pressure by dilating blood vessels are
called antihypertensive drugs. Novel antihypertensive drugs are Atenolol,
Amlodipine  and Nifedipine.
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(j)        Anti-AIDS drugs
          Drugs, which kills the viruses of AIDS i.e., HIV-1 and HIV-2 are called
anti-AIDS drugs. Novel drugs are Zidovudine, Acyclovir  and Didanosine .
(k) Antacid drugs
           Drugs, which neutralize the acid in stomach and stops excessive
secretion of acid, are called antacid drugs. Novel antacid drugs are Omeprazole
and Lansoprazole.
(l)      Non steroidal antiinflammatory drugs (NSAID)
Drugs, which gives relief from fever, pain and inflammation are called
NSAID. Novel NSAID are Pyroxicam , Meloxicam  and Nimesulide.
Different kind of drugs generally used are designed as anaesthetic,
anti tuberculostat ic, antihypertensive, anticonvulsant, anthelmintic,
antiinflammatory, sedative and hypnotics which prompted us to synthesise drugs
having pyrazolo[3,4-d]pyrimidines, quinazolines and pyrazoles  moieties as
a better therapeutic activity.
n Aims and objectives of the present investigation are
(a) To generate several biologically active moieties such as pyrazolo[3,4-d]
pyrimidines, quinazolines and pyrazoles .
(b) To characterize these products for their structural assignment using various
             spectroscopic techniques like IR, PMR and Mass spectroscopy.
(c) To screen these new derivatives for their antimicrobial activity using different
strains of bacteria and fungi and to compare antimicrobial activity with
different known drugs at different concentrations for their MIC values.
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In view of these facts, the research work presented in thesis are as follows.
    ( A )   STUDIES ON  PYRIMIDINE  DERIVATIVES
    ( B )   STUDIES ON QUINAZOLINES DERIVATIVES
    ( C )   STUDIES ON PYRAZOLE DERIVATIVES
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Pyrazolo[3,4-d]pyrimidine (1)  is a fused heterocyclic compound in which
pyrimidine with its “ d” position is fused at 3,4-position of pyrazole ring. R. Justoni
et al.,1  have synthesized 6-methyl-1,3-diphenyl-1H-pyrazolo[3,4-d]pyrimidine-4-
(5H)-ones in 1938. Pyrazolo[3,4-d]pyrimidine ring is isomeric with the purine (2)
ring and therefore, is of interest as a model for biologically active compounds.
Pyrazolo[3,4-d]pyrimidine is also known as allopurine.
















(1)     (2)
Pyrazolo[3,4-d]pyrimidine  Purine ring system
There are two other possible isomers of pyrazolo[3,4-d]pyrimidines(3,4) ,
which are fused at different positions of pyrazole ring and are represented as under.










       (3)       (4)
     Pyrazolo[3,2-f]-1,2,4-triazine Pyrazolo[4,3-d]pyrimidine
METHODS FOR SYNTHESIS OF PYRAZOLO[3,4-d]PYRIMIDINES
Extensive studies have been made in the field of synthesis of pyrazolo[3,4-d]-
pyrimidines. Various methods for the synthesis of pyrazolo[3,4-d]pyrimidines have
been described as under:
(a) By the condensation of 5-amino-4-cyano-pyrazole with 5-nitro-2-furonitrile led
to formation of 4-amino-6-(5’-nitro-2’-furyl)-1H-pyrazolo[3,4-d]pyrimidines 2.
(b) By the cyclocondensation of 4,6-dichloro-5-formylpyrimidine with
20S t u d i e s  o n  P y r i m i d i n e s
hydrazine hydrate led to formation of 1H-pyrazolo[3,4-d]pyrimidines 3.
(c) By the fusion of 1,3-dimethyl-6-hydrazino uracil at 150oC with dimethyl forma-
mide dimethylacetal (DMFDMA) led to formation of 2-alkyl-5,7-dimethyl
pyrazolo[3,4-d]pyrimidine-4,6(5H, 7H)-diones 4.
(d) By the fusion of 5-arylazo-6-arylidene-hydrazino-1,3-dimethyl uracils at
200
o
C led to formation of 2-benzyl-5,7-dimethyl-3-phenylpyrazolo[3,4-d]-
pyrimidines-4,6(5H,7H)-diones 5.
(e) By the cyclocondensation of 5-amino-4-cyano pyrazole with guanidine  car-
bonate led to formation of 4,6-diaminopyrazolo[3,4-d]pyrimidines6.
(f) By the cyclocondensation of arylidene derivative of 1,3-diphenyl uracil
with hydrazine hydrate led to the formation of pyrazolo[3,4-d]pyrimidines7.
(g) By the cyclocondensation of 4-carboxamido-5-amino-1,2,3-trihydropyra-
zole with formamide led to the formation of pyrazolo[3,4-d]pyrimidines 8.
(h) By the cyclocondensation of 3,4-dicyano-5-amino-1-N-substituted pyrazole
with trichloro acetonitrile led to formation of pyrazolo[3,4-d]pyrimidines 9.
(i) By the cyclocondensation of 3-aryl-2-arylamino-5-cyano-6-methyl-sul-
phonylpyrimidine-4-one with hydrazine hydrate  led to formation of pyrazolo-
[3,4-d]pyrimidines 10.
(j) By the cyclization of 2-chloro-6-methoxy quinoline-3-carboxaldehyde and
3-methyl-1-N-phenyl-5-pyrazolone with thiourea led to formation of pyra-
zolo[3,4-d]pyrimidines 11.
(k) By the cyclization of substituted 5-amino-1H-pyrazole-4-carbonitrile with
formic  acid, carbon disulphide, formamide, urea, thiourea and guanidine12.
(l) By the cyclization of substituted ethyl-(4-cyano-1H-pyrazol-5-yl)imidoformate
with ammonium hydroxide, hydrazine hydrazide and acid hydrazide12.
Pyrazolo[3,4-d]pyrimidines were found to possess remarkable bio-
logical activities viz. 1-aryl-3-methyl-6-mercapto-4,5-dihydropyrazolo[3,4-
d]pyrimidine (5) shows fungicidal11 activity, [1,6-dimethyl-5-(2-methyl phe-
nyl)-1,5-dihydro pyrazolo[3,4-d]pyrimidine-4-ylidine]methyl aniline (6)
shows  pesticidal 13,14   activity and 6-[aryl(diflouro)methyl)-3-aryl-1,5-dihydro
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(5)                                       (6)                                                     (7)
                                                                                          R = Ph / 4-CI-C 6H4
PHARMACOLOGICAL SIGNIFICANCE OF PYRAZOLO[3,4-d]PYRIMIDINES
Considerable research has been undertaken to extend the activity and
reduce toxicity of Pyrazolo[3,4-d]pyrimidines. The specific biological activities
of  Pyrazolo[3,4-d]pyrimidines have been represented as under.
(a) Hyperglycemia 16,17 (b) Protozoacidal 18
(c) Hypoglycemia 19 (d) Antimalarial 20
(e) Anticancer 21-24 (f) Analgesic, antipyretic,
antiinflammatory 25-28
(g) Antimycotic agent 29 (h) Xanthine oxidase inhibitor 30,31
(i) Antitumor 32-34 (j) Anti HIV 35
(k) Anxiolytic agent 36 (l) Cardiovascular 37,38
(m) Antileishmanial 39-41 (n) Tranquilizer 42
(o) Blood sugar lowering agent 43(p) Antiparasitic 44
(q) Antianaphylactic agent 45 (r) Coccidiostatic agent 46
(s) Anticonvulsant 47 (t) Antiviral 48
(u) Antiallergic 49 (v) Antimicrobial activity49a
F. Robert et al., 50 have conducted the studies of pyrazolo[3,4-d]pyrimi-
dine as a chemotherapeutic agent against neurospora. The family of 4-amino
pyrazolo[3,4-d]pyrimidines linked at 3 and 1 position by pyridoxine and pyridox-
amine which are involved in a thiamine metabolism and which are linked by se-
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ries of related compounds adenine, thiamine, caffeine and some vitamins can
exhibit neurospora growth. E. Harward et al.,51 evaluated 4-amino pyrazolo[3,4-
d]pyrimidines and its methyl derivative as significant growth inhibitor of
adrenocarcinoma 755 in mice. Machon et al.,52 have  synthesized pyrazolo[3,4-
d]pyrimidines  (8) which possess carcinostatic activity at 50 mg/ml, gave 71 - 76%
inhibitor respective of Ehrlich Carcinoma in mice. Dobrynine et al.,53 have tested
3,4-disubstituted-6-(methylmercapto)pyrazolo[3,4-d]pyrimidines (9) for cyto-
toxic activity on a human overian carcinoma cell and antiviral activity against Herpes
and Pox infection in chicken fibroblasts.

















R=H, R 1=SMe, R2,R3=SH/SMe/OCH3
Fusishita et al.,54 have synthesized pyrazolo[3,4-d]pyrimidines (10) as
angiotensin (II) antagonists. R. P. Tripathi et al.,55 have synthesized 2',2'-anhydro
nucleosides of pyrazolo[3,4-d]pyrimidines (11)  as antiviral agents.



















    (10)                   (11)
M.L. Taha et al.,56  have synthesized 1-(2-hydroxyethoxymethyl)
pyrazolo[3,4-d]pyrimidines (12) as anti HIV agents.Oocta et al., 57 have prepared
1H-pyrazolo[3,4-d]pyrimidines (13) as potent antihypertensive and cardio-
vascular agent.
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Y. Xia et al.,58 have synthesized polycyclic pyrazolo[3,4-d]pyrimidines
(14) and evaluated as PDE-1, PDE-5, CGMF-phosphodiesterase inhibitor. This
compound was also a  good orally active antihypertensive in laboratory. A. Straub















            (14)          (15)
Recently,  A.S. Bell et al.,60 have prepared pyrazolo[3,4-d]pyrimidines (16)
which are useful for treatment of memory enhancement, hypertension, congestive











M. Friedman et al.,61 have prepared 3-(azo hetero)aryl-1H- pyrazolo[3,4-
d] pyrimidine-3-amines (17)  as protein kinase inhibitors with antiangiogenic
properties.












J. Markwalder et al.,62 have synthesized 6-substituted pyrazolo[3,4-d]-
pyrimidin-4-ones (18)  useful as cyclin dependent kinase (cdk) inhibitors for treat-
ing cancer and proliferative diseases. M. M. Ghorab et al.,63 have synthesized
novel series of pyrazolo[3,4-d]pyrimidine (19) and evaluated for antimicrobial
activity comparable to antibiotic Chloramphenicol as standard antibacterial
























M. L. Taha et al.,64 have synthesized pyrazolo[3,4-d]pyrimidine (20,21,22)
and were evaluated for their inhibitory effects against the replication of HIV-1(IIIB),
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Lilia M. Beauchamp et al.,65 have synthesized pyrazolo[3,4-d]pyrimidine (23)
which are inhibitors of the enzyme purine nucleoside phosphorylase(PNPase)
with Ki’ values ranging from 0.05 to 1.6 mM. These compounds are enzymatically
stable congeners of the potent PNPase inhibitor acyclovir diphosphate. Donald F.
Smee et al.,66 have prepared novel pyrazolo[3,4-d]pyrimidine(24) nucleoside along with



















The most successful and well understood pyrazolo[3,4-d]pyrimidine com-
pound is acyclovir (25),  which is highly active against herpes simplex virus (HSV),
varicella zoster virus infections and is used clinically. 67,68 Acyclovir is a 2’-
deoxyguanosine analoge that contains an acyclic side chain in place of the deox-
yribose ring. It contains all of the atoms of 2’-deoxyguanosine, with the exception









Like most nucleoside analogues, acyclovir is a prodrug. Unlike other
necleoside analogs such as 3-Azido-3’deoxythymidine(AZT), however, prodrug
activation is one of the mechanisms by which acyclovir obtains selectivity. The
compound has a selectivity index of approximately 3000; the IC 50 is 300mM for
inhibition of HSV-1, while the IC 50 is 300mM for cytotoxicity to host Vero cells in
vitro.67 This selectivity is derived from two different mechanisms: Differential ac-
tivation of acyclovir in infected cells and increased potency against HSV DNA
polymerase. Acyclovir is phosphorylated 30-120 times faster with extracts from
HSV-1-infected cells compared to uninfected cell extracts.68 Moreover, the ki
(23) (24)
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values for HSV-encoded DNA polymerases are 10-40 times lower than for cellu-
lar DNA polymerases.67 Thus the active form of acyclovir is present in greter
quntities within virally infected cells and is also more potent against viral DNA
polymerase.
Activation of acyclovir to its triphosphate form is mediated by both viral
and cellular enzymes. Virally encoded thymidine kinase produces acyclovir mono-
phosphate, which is further phosphoryalated by cellular GMP kinase to the diphos-
phate derivative. The diphosphate is converted to acyclovir triphosphate deriva-
tive by cellular kinases such as phosphoglycerate kinase. There are several lines
of evidence that supports HSV thymidine kinase as a key enzyme for the antiviral
effect of acyclovir. 67 Perhaps the most convincing evidence is derived from stud-
ies with thymidine kinase-deficient mutants of HSV, which are resistant to acyclovir
because no phosphorylation occurs within infected cells.
The triphosphate form of acyclovir inhibits DNA polymerase. The mecha-
nism of inhibition is complex and may involve enzyme inactivation.69 Initially, the
compound competes with dGTP for binding to the polymerase-template complex.
Following binding, it has been suggested that enzyme inactivation occurs by the
formation of a tight,irreversible enzyme-DNA-acyclovir triphosphate ternary com-
plex. Addition of dGTP to this complex does not release active viral DNA poly-
merase. Interestingly, DNA polymerase from the host cell is not inactivated in this man-
ner. In addition to dGTP complition and enzyme inactivation,acyclovir triphosphate
inactivates the viral DNA template by chain termination, since it does not contain
3’-OH group necessary for the addition of subsequent dNTPs.70 In virally infected
cells, incomplete DNA replication occurs upon treatment with acyclovir. 71
Several analoges of acyclovir have been investigated, both at the level
of the target enzymes and for antiviral effect. Various alterations to the ali-
phatic side chain of acyclovir are tolerated by the HSV thymidine kinase, as long
as the terminal hydroxy group is retained for phosphorylation72. However, the en-
zyme is far less tolerant of modification to the heterocyclic base moiety. Since
the pyrimidines are the natural substrates for the viral thymidine kinase, it seems
logical to predict that pyrimidine analogs of acyclovir might be good kinase sub-
strates and antiviral agents. However, this is not the case. Similarly, among pu-
rine analogs, only those containing guanine are good substrates for the viral
enzyme72.
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Gaciclovir (26) is an acyclovir analogs that contains an additional
hydroxymethyl group in the side chain73. Because this compound contains groups
that mimic both, the 5’-OH and 3’-OH groups of deoxyguanosine, it does not act
as a chain terminator for DNA synthesis. Nevertheless, compound (27) is selec-
tively phosphorylated by the viral thymidine kinase and, as the triphosphate form,
inhibits Herpes Simplex virus-1(HSV-1, HSV-2) polymerase76. Gaciclovir has
been reported to be superior to acyclovir against human cytomegalovirus (HCMV).
Although the compound is converted to the triphosphate form in HCMV-infected
cells, the enzymes responsible for this transformation are not yet known. There is
no evidence that HCMV encodes a thymidine kinase.
`Among acyclovir analogs, the cyclic monophosphate derivative has been
reported to have the broadest spectrum of activity against DNA viruses.68,75
Within cells, compound (27) is converted to the (S) enantiomer of ganciclovir mono-
phosphate (28), the same compound that is obtained from phosphorylation of
(26) by HSV-1 thymidine kinase. Other analogs that have been prepared includes
compound (29) and a series of related derivatives68,76. These compounds have







































(26)           (27)                (28)     (29)
In view of procuring highly potent biodynamic agents and after reviewing
literature survey on pyrazolo[3,4-d]pyrimidines for their various  pharmacological
activities, synthesis of pyrazolo[3,4-d]pyrimidines have been undertaken which
can be summarized in the following section as under.
SECTION - I    : Preparation and biological evaluation of 3-Methyl-
4-aryl-6-mercaptomethyl-4,5-dihydro-1H-pyrazolo-
[3,4-d]pyrimidines.
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SECTION - II : Preparation and biological evaluation of  3- Methyl-
4-aryl-6-methylsulfonyl-1H-pyrazolo[3,4-d]
pyrimidines
SECTION - III : Preparation and biological evaluation of 3-Methyl-
4-aryl-6-hydrazino-4,5-dihydro-1H-pyrazolo[3,4-d]-
pyrimidines.
SECTION - IV : Preparation and biological evaluation of 3-Methyl-
4-aryl-6-(2’,4’- dinitrophenyl)thio-4,5-dihydro-1H-
pyrazolo[3,4-d]pyrimidines.
SECTION - V : Preparation and biological evaluation of 3-Methyl-
4-aryl-6-mercaptomethyl-1-N-phenyl-4,5-dihydro-1H-
pyrazolo[3,4-d]pyrimidines.
SECTION - VI : Preparation and biological evaluation of 3-Methyl-
4-aryl-6-methylsulfonyl-1-N-phenyl-pyrazolo[3,4-d]-
pyrimidines.
SECTION-VII : Preparation and biological evaluation of 3-Methyl-
4-aryl-6-hydrazino-1-N-phenyl-4,5-dihydro-1H-
pyrazolo[3,4-d]pyrimidines.
SECTION - VIII : Preparation and biological evaluation of 3-Methyl-
4-aryl-6-(2’,4’-dinitrophenyl)thio-1-N-phenyl-4,5-
dihydro-1H-pyrazolo[3,4-d]pyrimidines.
SECTION - IX : Preparation and biological evaluation of 3-Methyl-
4-(1’-N-phenyl-3’-aryl pyrazol- 4’-yl)-6-hydroxy-4,5-
dihydro-1H-pyrazolo[3,4-d]pyrimidines.
SECTION - X : Preparation and biological evaluation of 3-Methyl-
4-(1’-N-phenyl-3’-aryl pyrazol- 4’-yl)-6-mercapto-4,5-
dihydro-1H-pyrazolo[3,4-d]pyrimidines.
SECTION - XI : Preparation and biological evaluation of 3-Methyl-
4-(1’-N- phenyl-3’-aryl pyrazol-4 ’-yl)-6-amino-4,5-
dihydro-1H-pyrazolo[3,4-d]pyrimidines.
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SECTION - I
 PREPARATION  AND BIOLOGICAL EVALUATION OF 3-METHYL-4-
ARYL-6-MERCAPTOMETHYL-4,5-DIHYDRO-1H-PYRAZOLO[3,4-d]PYRIMIDINES.
Keeping in view, wide spectrum of b iodynamic  ac t i v i t i es16-49 o f
pyrazolo[3,4-d]pyrimidines and with a view to have potent therapeutic agents, the
synthesis of 3-methyl-4-aryl-6-mercapto methyl-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidine (a1-10) have been undertaken by the reaction of different 3-methyl-
4-aryl-6-mercapto-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines with dimethyl sulphate
in the presence of a base.
The constitution of the products (a1-10) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (a1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibitory
Concentration) values. The biological activities of the synthesized compounds










(a1-10)                 R=Aryl
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL  EVALUATION OF 3-METHYL-4-ARYL-6-
MERCAPTOMETHYL-4,5-DIHYDRO-1H-PYRAZOLO[3,4-d]PYRIMIDINES.
(A) Preparation of 3-methyl-4-( p-methoxyphenyl)-6-mercapto-4,5-
dihydro-1H-pyrazolo[3,4-d]pyrimidine.
A mixture of 5-methyl-2,4-dihydro-3H-pyrazol-3-one (0.98 gm, 0.01M),p-
methoxy benzaldehyde (1.36 ml, 0.01 M), and thiourea (0.76 gm, 0.01 M) in etha-
nol(30 ml) was heated under reflux condition for 8-10 hrs. The reaction     mixture
was kept at room temperature for two hrs. The yellow crystalline product  ob-
tained was isolated and recrystallized from ethanol. Yield : 72%, M.P. : 150°C, Rf
: (1) 0.57 (2) 0.61 (Required : C, 56.93%; H, 5.11%; N, 2 0.44% for C 13H14N4OS,
Found : C, 5 6.88%; H, 5.07%; N, 20.40%).
Similarly, other compounds (I1-10) were synthesized. The physical data are
recorded in Table-I.
(B) Preparation of 3-Methyl-4-(p-methoxyphenyl)-6-mercaptomethyl-
4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine (a10).
A mixture of 3-methyl-4-(p-methoxyphenyl)-6-mercapto-4,5-dihydro-1H -
pyrazolo[3,4-d]pyrimidine (2.74 gm, 0.01M),dimethyl sulphate (1.26 ml,0.01 M)
and potassium carbonate in DMF (30 ml) was stirred for 4 hrs. The reaction mix-
ture was poured into crused ice. The product was filtered and recrystallized from
ethanol. Yield : 68%, M.P. : 154°C, Rf : (1) 0.62 (2) 0.63 (Required : C, 59.26%;
H, 5.35%; N, 28.81% for C 14H16N4OS, Found : C, 59.20%; H, 5.30%; N, 28.75%).
Similarly, other compounds (a1-10) were synthesized. The physical data
are recorded in Table No. 1.
(C) Antimicrobial activity of 3-Methyl-4-aryl-6-mercaptomethyl-4,5-di-
hydro-1H-pyrazolo[3,4-d]pyrimidines (a1-10).
Antimicrobial activity testing was carried out by using cup-plate method77,
which has been described as under.
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 * Antibacterial activity
S. pyogens MTCC-442 and S. aureus MTCC-96 (Gram posit ive
bacteria) were grown in nutrient broth and E. coli MTCC-443 and B. subtillis
MTCC-441 (Gram negative bacteria) in Peptone water (PW, 1% bacteriological
peptone and 0.5% NaCl) for 24 hrs., this gave an optimum growth of the test
bacteria. Each purified compound was dissolved in DMF sterilized by filtration
by using sintered glass filter and stored at 4°C. Each agent was then added to
molten nutrient agar in the following concentrations (µg/ml) : 0 (control), 5, 10, 25,
50, 100, 200, 500 and poured into sterile petri dished. The pH of the medium was
maintained at 7.2 -7.4. The inoculum consisted of an overnight grown broth
culture of a bacterium diluted in such a manner that a 2 mm (internal diameter)
loopful of the culture contain 105 colony-forming unit (CFU). These were then spot
inoculated on nutrient  agar  plates containing increasing amount of a
compound, incubated at 37°C up to 24 hrs. for determination of the minimum
inhibitory concentration78,79  (MIC). Which are recorded in zones of inhibition in
mm for bacterias.
   * Antifungal activity
C. albicans MTCC-227 and A. niger MTCC-282 was employed for
testing antifungal activity using cup-plate method. The culture was maintained on
Sabouraud's agar for 72 hrs., this gave an optimum growth of the test fungal
spores. Each purified compound was dissolved in DMF sterilized by filtration by
using sintered glass filter and stored. Each agent was then added to Sabouraud's
agar in the following concentrations (µg/ml): 0 (control), 5, 10, 25, 50, 100, 200,
500 and poured into sterile petri dished. The inoculum consisted of an overnight
grown broth culture of a bacterium diluted in such a manner  than a 2 mm (internal
diameter) loopful of the culture contain 105 colony-forming unit (CFU). These were
then spot inoculated on Sabouraud's agar plates containing increasing amount
of a compound, incubated at 37°C up to 48 hrs. for determination of the minimum
inhibitory concentration (MIC)78,79. The MIC values of test solutions are
recorded in Table No. 1a, 1b & 1c .  Which are recorded in zones of inhibition in
mm for fungii.
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SECTION - II
Preparation and biological evaluation of 3-Methyl-4-aryl-
6-methylsulfonyl-1H-pyrazolo[3,4-d]pyrimidines.
Keeping in view, wide spectrum of b iodynamic  ac t i v i t i es16-49 o f
pyrazolo[3,4-d]pyrimi- dines and in order to have highly potent  therapeutic agents,
the synthesis of 3-Methyl-4-aryl-6-methylsulfonyl-1H-pyrazolo[3,4-d]pyrimidines
(b1-10) have been undertaken by the oxidation of 3-Methyl-4-aryl-6-mercapto-











The constitution of the products (b1-10) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (b1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(b1-10)                R=Aryl
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m/z = 304 (M-2)
m/z = 288 
m/z = 259 (M+2)
m/z = 196 (M-2)
m/z = 186 (M-2)
m/z = 173m/z = 146
m/z = 133
m/z = 120 (M+2)
m/z = 98
m/z = 77 (BP)
m/z = 317 (M+)
(b10)
47S t u d i e s  o n  P y r i m i d i n e s
REACTION SCHEME
























48S t u d i e s  o n  P y r i m i d i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-ARYL-6-
METHYLSULFONYL-1H-PYRAZOLO[3,4-d]PYRIMIDINES (b 1-10).
(A) Preparation of 3-Methyl-4-(p-methoxyphenyl)-6-mercapto methyl-
4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine.
            For preparation, refer Part-I, Section-I, Page No. 35.
(B) Preparation of 3-Methyl-4-(p-methoxyphenyl)-6-methylsulfonyl-1H-
pyrazolo[3,4-d]pyrimidine (b 10).
A mixture of 3-Methyl-4-(p-methoxyphenyl)-6-methylthio-4,5-dihydro-1H-
pyrazolo[3,4-d]pyrimidine (2.88 gm, 0.01M) in gla. acetic acid and 10ml of hydro-
gen peroxide was stirred for 48 hrs. at room temperature.The content was poured
into ice cold water and filtered. The product was isolated and crystallized from
ethanol. Yield : 68%, M.P. : 168°C, Rf1 : 0.52, Rf2 : 0.55 (Required : C, 52.50%;
H, 5.00%; N, 17.50% for C14H14N4O3S, Found : C, 52.45%; H, 4.96% ; N,
17.45%).
.
Similarly, other compounds (b1-10) were synthesized. The physical data are
recorded in Table No. 2.
(C) Antimicrobial activity of 3-Methyl-4aryl-6-methylsulfonyl-1H-pyrazolo[3,4-d]-
pyrimidines (b 1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
2a, 2b & 2c.
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SECTION - III
Preparation and biological evaluation of 3-Methyl-4-
aryl-6-hydrazino-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines.
Keeping in view, wide spectrum of b iodynamic  ac t i v i t i es16-49 o f
pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic agents,
the synthesis of 3-Methyl-4-aryl-6-hydrazino-4,5-dihydro-1H-pyrazolo[3,4-
d]pyrimidines (c1-10) have been undertaken by the reaction of 3-Methyl-4-aryl-6-










The constitution of the products (c1-10) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (c1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
     (c1-10)               R=Aryl
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m/z = 271 (M-2)




m/z = 161 (BP)
m/z = 134
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REACTION SCHEME



























59S t u d i e s  o n  P y r i m i d i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-ARYL-6-
HYRAZINO-4,5-DIHYDRO-1H-PYRAZOLO[3,4-d]PYRIMIDINES.
(A) Preparation of 3-Methyl-4-(p-methoxyphenyl)-6-methylthio-4,5-dihydro-
1H-pyrazolo [3,4-d]pyrimidine (a10).
            For preparation, refer Part-I, Section-I, Page No. 35
(B) Preparation of 3-Methyl-4-(p-methoxyphenyl)-6-hydrazino-4,5-dihydro-
1H-pyrazolo[3,4-d]pyrimidine (c10).
A mixture of 3-Methyl-4-aryl-6-methylthio-4,5-dihydro-1H-pyrazolo[3,4-d]-
pyrimidine (4.73gm, 0.01M) and hydrazine hydrate(0.32gm, 0.01M) was heated
under reflux condition for 10 hrs. The content was poured into ice cold water and
filtered. The product was isolated and crystallized from ethanol. Yield : 65%, M.P.
: 158°C, Rf1 : 0.58,Rf2 : 0.61(Required : C, 52.35%; H, 5.88%; N, 30.88% for
C13H16N6O, Found : C, 52.30%; H, 5.84% ; N, 30.81%).
.
Similarly, other compounds  (c1-10) were synthesized. The physical data are
recorded in Table No. 3.
(C) Antimicrobial activity of 3-Methyl-4-aryl-6-hydrazino-4,5-dihydro-1H-
pyrazolo[3,4-d]pyrimidines (c1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
3a, 3b & 3c.
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c 1 c 2 c 3 c 4 c 5 c 6 c 7 c 8 c 9 c 1
0
   
   
   
   
































































































































































































































c 1 c 2 c 3 c 4 c 5 c 6 c 7 c 8 c 9 c 1
0
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SECTION - IV
Preparation and biological evaluation of 3-Methyl-4-aryl-
6-(2’,4’- dinitrophenyl)thio-1H-pyrazolo[3,4-d]pyrimidines.
Keeping in view, wide spectrum of b iodynamic  ac t i v i t i es16-49 o f
pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic agents,
the synthesis of 3-Methyl-4-aryl-6-(2’,4’- dinitrophenyl)thio-1H-pyrazolo[3,4-
















The constitution of the products (d1-10) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (d1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(d1-10)                R=Aryl
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PMR SPECTRAL STUDY OF 3-METHYL-4-(p-METHOXYPHENYL)-6-(2’,4’-
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-ARYL-6-
(2’,4’-DINITROPHENYL)THIO-4,5-DIHYDRO-1H-PYRAZOLO[3,4-d]PYRIMI-
DINES.
(A) Preparation of 3-methyl-4-(p-methoxyphenyl)-6-mercapto-4,5-dihydro-1H-
pyrazolo[3,4-d]pyrimidine.
            For preparation refer Part-I, Section-I, Page No.35.
(B) Preparation of 3-methyl-4-(p-methoxyphenyl)-6-(2’,4’-dinitrophenyl)thio-
4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine (d10).
A mixture of 3-methyl-4-(p-methoxyphenyl)-6-mercapto-4,5-dihydro-1H-pyrazolo-
[3,4-d]pyrimidine (4.73gm, 0.01M) and 1-chloro-2,4-dinitrobenzene (2.02gm, 0.01M)
was heated under reflux condition for 10 hrs. The content was poured into ice
cold water and filtered. The product was isolated and crystallized from ethanol.
Yield : 65%, M.P. : 175°C, R f1 : 0.50 , R f2 : 0.53 (Required : C, 51.82%; H, 3.64%;
N, 19.09% for C 19H16N6O5S, Found : C, 51.77%; H, 3.60% ; N, 19.05%).
.
Similarly, other compounds (d1-10) were synthesized. The physical data are
recorded in Table No. 4.
(C) Antimicrobial activity of 3-methyl-4-(p-methoxyphenyl)-6-(2’,4’-dinitro-
phenyl)thio-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines (d1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
4a, 4b & 4c.



















































































































   
























































   








































   








































   










































   










































   








































   









































   







































   
   





   









































   











































   
















































   
   
   
   
   
   
   


















   



































































































   




























































   
   
   
   













   
   
   
   
   
   
   
   
   
   
   
   
   
   
   



























































































































































   






































































































































































































   
   
   
   

























































































































































































































k 7 k 1
0
k 7 k 1
0
k 2 k 1
0
k 6
k 1 k 6 k 1
0
k 1 k 4 k 9
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SECTION - V
Preparation and biological evaluation of 3-Methyl-4-aryl-
6-mercaptomethyl-1-N-phenyl-4,5-dihydropyrazolo[3,4-d]
pyrimidines.
Keeping in view, wide spectrum of b iodynamic  ac t i v i t i es16-49 o f
pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic agents,
the synthesis of 3-Methyl-4-aryl-6-mercaptomethyl-1-N-phenyl-4,5-dihydro-
pyrazolo[3,4-d]pyrimidines (e1-10) have been undertaken by the reaction of
different 3-methyl-4-aryl-6-mercapto-1-N-phenyl-4,5-dihydropyrazolo[3,4-d]pyrimidines










The constitution of the products (e1-10) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (e1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(e1-10)                R=Aryl

























700 -   600




















































































77S t u d i e s  o n  P y r i m i d i n e s










































































































































































































































m/z = 320 m/z = 306 (M-1) m/z = 286 (M-1)
m/z = 265 (M+1)
m/z = 254 (M-2)
m/z = 244
m/z = 230 (M-1)
m/z = 215 (M+2)m/z = 188




m/z = 124 (M-1)
m/z = 110 (M+1) (BP)
m/z = 96 (M -1)
m/z = 82 (M-1)
(e10)
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REACTION SCHEME






































81S t u d i e s  o n  P y r i m i d i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3- METHYL-4-ARYL-6-
MERCAPTOMETHYL-1-N-PHENYL-4,5-DIHYDROPYRAZOLO[3,4-d]PYRI-
MIDINES.
(A) Preparation of 3-methyl-4-(p-methoxyphenyl)-6-mercapto-1-N-phenyl-4,5-
dihydropyrazolo[3,4-d]pyrimidine.
A mixture of 5-methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (1.74 gm,
0.01M),p-methoxybenzaldehyde (1.36 ml, 0.01 M) and thiourea (0.76 gm, 0.01
M) in ethanol(30 ml) was heated under reflux condition for 8-10 hrs. The reaction
mixture was kept at room temperature for two hrs. The yellow crystalline
product obtained was isolated and recrystallized from ethanol. Yield : 75%, M.P. :
164°C.
(B) Preparation of 3-Methyl-4-aryl-6-mercaptomethyl-1-N-phenyl-4,5-dihydro-
pyrazolo[3,4-d]pyrimidine (e10).
A mixture of 3-methyl-4-(p-methoxyphenyl)-6-mercapto-1-N-phenyl-4,5-dihydro-
pyrazolo[3,4-d]pyrimidine (3.50 gm, 0.01M),dimethyl sulphate (1.26 ml,0.01 M)and
potassium carbonate (2.0 gm) in DMF(30 ml) was stirred for 4hrs. The reaction
mixture was poured into crused ice. The product was filtered and crystallized from
ethanol. Yield : 65%, M.P. : 164°C, R f1 :0.44 , R f2 :0.45 (Required : C, 65.93%; H,
5.49%; N, 15.38% for C 20H20N4OS, Found : C, 65.90%; H, 5.44%; N, 15.31%).
Similarly, other compounds (e1-10) were synthesized. The physical data are
recorded in Table No. 5.
(C) Antimicrobial activity of 3-Methyl-4-aryl-6-mercaptomethyl-1-N-phenyl-4,5-
dihydropyrazolo[3,4-d]pyrimidines (e1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
5a, 5b & 5c.
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SECTION - VI
Preparation and biological evaluation of 3-Methyl-4-aryl-
6-methylsulfonyl-1-N-phenylpyrazolo[3,4-d]pyrimidines.
Keeping in view, wide spectrum of b iodynamic  ac t i v i t i es16-49 o f
pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic agents,
the synthesis of 3-Methyl-4-aryl-6- methylsulfonyl-1-N-phenylpyrazolo[3,4-













The constitution of the products (f1-10) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (f1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(f1-10)                R=Aryl
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m/z = 77 
m/z = 364(m+2)
m/z = 335(m+2)






m/z = 171(m -2)
m/z = 145(m -1)
m/z = 120(m -1)
m/z = 92(m -1)
(f1)
91S t u d i e s  o n  P y r i m i d i n e s
REACTION SCHEME
























92S t u d i e s  o n  P y r i m i d i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-ARYL-6-
METHYLSULFONYL-1-N-PHENYLPYRAZOLO[3,4-d]PYRIMIDINES.
(A) Preparation of 3-Methyl-4-(p-methoxyphenyl)-6-mercapto methyl-
1-N-phenyl-4,5-dihydropyrazolo[3,4-d]pyrimidine (e10).
            For preparation refer Part-I, Section-V, Page No. 81.
(B) Preparation of 3-Methyl-4-(p-methoxy phenyl)-6-methylsulfonyl-1-N-
phenyl-pyrazolo[3,4-d]pyrimidine (f10).
A mixture of 3-Methyl-4-(p-methoxyphenyl)-6-mercaptomethyl-1-N-phenyl-
4,5-dihydropyrazolo[3,4-d]pyrimidine (3.64gm, 0.01M) in gla. acetic acid and
10 ml of hydrogen peroxide was stirred for 48 hrs. at room temperature.The con-
tent was poured into ice cold water and filtered. The product was isolated and
crystallized from ethanol. Yield : 50%, M.P. : 178°C, Rf1 : 0.51, Rf2 : 0.54 (Re-
quired : C, 60.91%; H, 5.08%; N, 14.14% for C 20H18N4O3S, Found : C, 60.88%;
H, 5.04% ; N, 14.10%).
Similarly, other compounds (f1-10) were synthesized. The physical data are
recorded in Table No. 6.
(C) Antimicrobial activity of 3-Methyl-4-aryl-6-methylsulfonyl-1-N-phenyl-
pyrazolo[3,4-d]pyrimidines (f1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
6a, 6b & 6c.


































































































































































   








































   








































   










































   










































   








































   









































   







































   
   





   









































   











































   
















































   
   
   
   
   
   
   


















   































































































































































































































































   








































































































































































































































































































































































































































































































































































































































































































































































































































































































   




























































































































































































































































































































































































































































































































































































































































































































































































   














































































































































































































































































































































97S t u d i e s  o n  P y r i m i d i n e s
SECTION - VII
Preparation and biological evaluation of 3-Methyl-4-aryl-6-
hydrazino-1-N-phenyl-4,5-dihydropyrazolo [3,4-d]pyrimidines.
Keeping in view, wide spectrum of biodynamic activit ies 16-49  o f
pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic agents,
the synthesis of 3-Methyl-4-aryl-6-hydrazino-1N-phenyl-4,5-dihydropyrazolo[3,4-
d]pyrimidines (g1-10) have been undertaken by the reaction of 3-Methyl-4-aryl-6-










The constitution of the products (g1-10) have been delineated by elemen-
tal analyses, IR, PMR  and Mass spectral data.
The products (g1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(g1-10)                R=Aryl
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m/z = 348 (M+1)
m/z = 331 (M-2)
m/z = 316 (M+1) m/z = 302 m/z = 288 (M+1)
m/z = 263 (M+2)
m/z = 77
m/z = 98
m/z = 248 (M+1)
m/z = 172 (M+1)
m/z = 238 (M -1)
m/z = 186
m/z = 200 (M+2)
m/z = 146 m/z = 134 (M-1)
m/z = 120 (M+2) m/z = 212 (M
+1)
(g10)
102S t u d i e s  o n  P y r i m i d i n e s
REACTION SCHEME






















103S t u d i e s  o n  P y r i m i d i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-ARYL-6-
HYRAZINO-1-N-PHENYL-4,5-DIHYDROPYRAZOLO[3,4-d]PYRIMIDINES.
(A) Preparation of 3-Methyl-4-(p-methoxyphenyl)-6-mercaptomethyl-1N-
phenyl-4,5-dihydropyrazolo [3,4-d]pyrimidine (g 10).
            For preparation refer Part-I, Section-V, Page No. 81
(B) Preparation of 3-Methyl-4-(p-methoxyphenyl)-6-hydrazino-1N-phenyl-
4,5-dihydropyrazolo [3,4-d]pyrimidine (g 10).
A mixture of 3-Methyl- 4-aryl-6-methylthio-1-N-phenyl-4,5-dihydro
pyrazolo [3,4-d]pyrimidine (3.62gm, 0.01M) and hydrazine hydrate (0.32gm, 0.01M)
was heated under reflux condition for 10 hrs. The content was poured into ice
cold water and filtered. The product was isolated and crystallized from ethanol.
Yield : 54%, M.P. : 178°C, Rf1 : 0.53,Rf2 : 0.48(Required : C, 65.52%; H, 5.75%;
N, 24.14% for C 19H20N6O, Found : C, 65.47%; H, 5.70% ; N, 24.10%).
.
Similarly, other compounds  (g1-10) were synthesized. The physical data are
recorded in Table No. 7.
(C) Antimicrobial activity of 3-Methyl-4-aryl-6-hydrazino-1-N-phenyl-4,5-
dihydropyrazolo [3,4-d]pyrimidines (g 1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
7a, 7b & 7c.




































































































































































   





































   






































   







































   







































   





































   







































   






































   
   





   








































   









































   















































   
   
   
   
   
   
   


















   


























































































































































































































































   






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































   
   
































































































































































































































































































































































































































































































































































































































































































































































































   
   



































































































































































































































































































































































108S t u d i e s  o n  P y r i m i d i n e s
SECTION - VIII
Preparation and biological evaluation of 3-Methyl-4-aryl-6-
(2’,4’-dinitrophenyl)thio-1-N-phenyl-4,5-dihydropyrazolo[3,4-d]-
pyrimidines.
Keeping in view, wide spectrum of b iodynamic  ac t i v i t i es16-49 o f
pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic agents,
the synthesis of 3-Methyl-4-aryl-6-(2’,4’-dinitrophenyl)thio-1-N-phenyl-4,5-dihydro
pyrazolo[3,4-d]pyrimidines (h1-10) have been undertaken by the condensation of 3-















The constitution of the products (h1-10) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (h1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(h1-10)                R=Aryl
























700 -   600
3500 - 3310
1650 - 1580
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m/z = 246 m/z = 193(M+1)m/z = 133(M+1)





m/z = 77 
(h4)
113S t u d i e s  o n  P y r i m i d i n e s
REACTION SCHEME
































114S t u d i e s  o n  P y r i m i d i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3- METHYL-4-ARYL-6-
(2,4-DINITROPHENYL)THIO-4,5-DIHYDRO-1-N-PhenylPYRAZOLO[3,4-d]
PYRIMIDINES .
(A) Preparation of 3-methyl-4-(p-methoxyphenyl)-6-mercapto-1-N-phenyl-4,5-
dihydropyrazolo[3,4-d]pyrimidine.
            For preparation refer Part-I, Section-V, Page No.81.
(B) Preparation of 3-methyl-4-(p-methoxyphenyl)-6-(2’,4’-dinitrophenyl)thio-
1-N-phenyl-4,5-dihydropyrazolo[3,4-d]pyrimidine (h10).
A mixture of 3-methyl-4-(p-methoxyphenyl)-6-mercapto-1-N-phenyl-4,5-dihydro-
pyrazolo[3,4-d]pyrimidine (1.74gm, 0.01M) and 1-chloro-2,4-dinitrobenzene (2.02gm,
0.01M) heated under reflux condition for 10 hrs. The content was poured into ice
cold water and filtered. The product was isolated and crystallized from ethanol.
Yield : 55%, M.P. : 210°C, R f1 : 0.54 , R f2 : 0.56 (Required : C, 58.14%; H, 3.88%;
N, 16.28% for C 25H20N6O5S, Found : C, 58.10%; H, 3.84% ; N, 16.23%).
.
Similarly, other compounds (h1-10) were synthesized. The physical data are
recorded in Table No. 8.
(C) Antimicrobial activity of 3-methyl-4-(p-methoxyphenyl)-6-(2’,4’-dinitro-
phenyl)thio-1-N-phenyl-4,5-dihydropyrazolo[3,4-d]pyrimidines (h1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
8a, 8b & 8c.





















































































   
   
   
   
   
   
   


















   





























   








































   








































   










































   










































   








































   









































   







































   
   





   









































   











































   


















































































   






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































119S t u d i e s  o n  P y r i m i d i n e s
SECTION - IX
Preparation and biological evaluation of 3-Methyl-4-(1’-N-
phenyl-3’-arylpyrazol- 4’-yl)-6-hydroxy-4,5-dihydropyrazolo[3,4-d]
pyrimidines.
Keeping in view, wide spectrum of b iodynamic  ac t i v i t i es16-49 o f
pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic agents,
the synthesis of 3-Methyl-4-aryl-6-methylsulfonyl-1H-pyrazolo[3,4-d]pyrimidines
(i1-10) have been undertaken by the cyclocondensation of 5-methyl-2,4-dihydro-3H-










The constitution of the products (i1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (i1-8) were assayed for their in vitro biological assay like  an-
tibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(i1-8)                R=Aryl
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m/z = 121(M+1) m/z = 290(M-1)
m/z = 261
m/z = 133
m/z = 147(M -1)
m/z = 173
m/z = 187(M -1) m/z = 213 m/z = 225(M+1)
m/z = 249
(i3)
124S t u d i e s  o n  P y r i m i d i n e s
REACTION SCHEME























125S t u d i e s  o n  P y r i m i d i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL- 4-(1’-N-PHE-
NYL-3’ -ARYL-1H-PYRAZOL-4’ -YL)-6-MERCAPTO-4,5-DIHYDRO-1H-
PYRAZOLO[3,4-d]PYRIMIDINES.
(A) Preparation of 3-Methyl-4-(1’-N- phenyl-3’-(p-fluorophenyl)pyrazol-4’-yl)-
6-hydroxy-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine (i3).
A mixture of  3-(p-fluorophenyl)-1-N-phenyl-1H-pyrazole-4-carbaldehyde (2.66 gm,
0.01M), 5-methyl-2,4-dihydro-3H-pyrazol-3-one(0.98 gm,0.01M) and urea(0.60 gm, 0.01M)
was refluxed for 10 hrs. The reaction mixture was cooled at room temp. for 2 hrs.
The yellow crystlline product obtained was isolate d and recrystallized from ethanol.
Yield : 58%, M.P. : 188°C, Rf1 : 0.44, Rf2 :0.46 (Required : C, 64.95%; H, 4.38%;
N, 22.76% for C 21H17N6OF, Found : C, 64.90%; H, 4.35% ; N, 22.72%).
.
Similarly, other compounds (i1-8) were synthesized. The physical data are
recorded in Table No. 9.
(B) Antimicrobial activity of 3-Methyl-4-(1’-N- phenyl-3’-aryl-pyrazol-4’-yl)-
6-hydroxy-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines (i1-8).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
9a, 9b & 9c.
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130S t u d i e s  o n  P y r i m i d i n e s
SECTION - X
Preparation and biological evaluation of 3-Methyl-4-(1’-N-
phenyl-3’-arylpyrazol-4’-yl)-6-mercapto-4,5-dihydropyrazolo-1H-
[3,4-d]pyrimidines.
Keeping in view, wide spectrum of b iodynamic  ac t i v i t i es16-49 o f
pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic agents,
the synthesis of 3-Methyl-4-(1’-N-phenyl-3’-aryl pyrazol-4’-yl)-6-mercapto-4,5-dihydro
pyrazolo[3,4-d]pyrimidines ( j1-8 ) have been undertaken by the cyclisation of 5-me-











The constitution of the products ( j1-8 ) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products ( j1-8 ) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
( j1-8 )                R=Aryl
























700 -   600
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m/z = 224(M+2)m/z = 212(M+1)
m/z = 198
( j1)
135S t u d i e s  o n  P y r i m i d i n e s
REACTION SCHEME























136S t u d i e s  o n  P y r i m i d i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL- 4-(1’-N-PHE-
NYL-3’ -ARYL-1H-PYRAZOL-4’ -YL)-6-MERCAPTO-4,5-DIHYDRO-1H-
PYRAZOLO[3,4-d]PYRIMIDINES.
(A) Preparation of 3-Methyl-4-(1’-N- phenyl-3’-(p-fluorophenyl) pyrazol-4’-yl)-
6-mercapto-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine (j3).
A mixture of  3-(p-fluorophenyl)-1-N-phenyl-1H-pyrazole-4-carbaldehydes(2.66 gm,
0.01M), 5-methyl-2,4-dihydro-3H-pyrazol-3-one(0.96 gm, 0.01M) and thiourea(0.76 gm,
0.01M) was reflux for 10 hrs. The reaction mixture was cooled at room temp. for 2
hrs. The yellow crystlline product obtained was isolated and recrystallized from
ethanol. Yield : 52%, M.P. : 310°C, R f1 : 0.44, R f2 :0.49 (Required : C, 62.38%; H,
4.21%; N, 20.79% for C 21H17N6SF, Found : C, 62.35%; H, 4.16% ; N, 20.72%).
.
Similarly, other compounds (j1-8) were synthesized. The physical data are
recorded in Table No. 10.
(B) Antimicrobial activity of 3-Methyl-4-(1’-N- phenyl-3’-arylpyrazol-4’-yl)-
6-amino-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines (j1-8).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
10a, 10b & 10c.



































































   
   









































































































   






































   






































   








































   








































   









































   






































   







































   
   





   

























































   
   
   
   
   
   
   


















   















































































































































































j 1 j 2 j 3 j 4 j 5 j 6 j 7 j 8
   
   
   

































































































































































































































































































































































































































































































































































































j 1 j 3
j 3
j 2



















































































































































j 1 j 2 j 3 j 4 j 5 j 6 j 7 j 8
   
   
   


















































































































































































































































































































































































































































































































































































































































































































































j 1 j 2 j 3 j 4 j 5 j 6 j 7 j 8
   
   
   



















































































































































































































































































































































































































































































141S t u d i e s  o n  P y r i m i d i n e s
SECTION - XI
Preparation and biological evaluation of 3-Methyl-4-(1’-N-
phenyl-3’-arylpyrazol-4’-yl)-6-amino-4,5-dihydro-1H-pyrazolo -
[3,4-d]pyrimidines.
Keeping in view, wide spectrum of b iodynamic  ac t i v i t i es16-49 o f
pyrazolo[3,4-d]pyrimidines and in order to have highly potent therapeutic agents,
the synthesis of 3-Methyl-4-(1’-N- phenyl-3’-aryl pyrazol-4’-yl)-6-amino-4,5-dihydro-1H-
pyrazolo[3,4-d]pyrimidines (k1-8) have been undertaken by the cyclocondantation
of different 3-aryl-1-N-phenyl-1H-pyrazole-4-carbaldehydes, 5-methyl-2,4-dihydro-3H-










The constitution of the products (k1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (k1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(k1-8)                R=Aryl
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m/z = 290(M-1)m/z = 121(M
-1)
m/z = 121(M-1)
m/z = 147(M -1)




146S t u d i e s  o n  P y r i m i d i n e s
REACTION SCHEME























147S t u d i e s  o n  P y r i m i d i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-4-(1’-N-PHE-
NYL-3’-ARYL-1H-PYRAZOL-4’-YL)-6-AMINO-4,5-DIHYDRO-1H-PYRAZOLO[3,4-
d]PYRIMIDINES.
(A) Preparation of 3-Methyl-4-(1’-N- phenyl-3’-(p-fluorophenyl)pyrazol-4’-yl)-
6-amino-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidine (k3).
A mixture of  3-(p-fluorophenyl)-1-N-phenyl-1H-pyrazole-4-carbaldehyde
(2.66 gm, 0.01M), 5-methyl-2,4-dihydro-3H-pyrazol-3-one(0.98 gm, 0.01M) and
guanidine  hydrochloride (0.96 gm, 0.01M) was refluxed for 10 hrs. The reaction
mixture was cooled at room temp. for 2 hrs. The yellow crystlline product obtained
was isolated and recrystallized from ethanol. Yield : 60%, M.P. : 232°C, R f1 : 0.45,
Rf2 :0.48 (Required : C, 65.12%; H, 4.65%; N, 25.32% for C 21H18N7F, Found :
C, 65.06%; H, 4.61% ; N, 25.27%).
.
Similarly, other compounds  (k1-8) were synthesized. The physical data are
recorded in Table No. 11.
(B) Antimicrobial activity of 3-Methyl-4-(1’-N- phenyl-3’-arylpyrazol-4’-yl)-
6-amino-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidines (k1-8).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
11a, 11b & 11c.
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Quinazoline (30) is a host of compounds which are associated with wide











The 4-ketoquinazolines have both, animal and plant origin. The glomerin
(31) and homoglomerin(32) are the quinazolinone derivatives produced by Eu-











Extensive studies have been made in the field of synthesis of Quinazolines.
Several methods have been reported in literature82-84 for the synthesis of
quinazoline which are discribed as under.
(1) By the heating of arylaminobenzanilides led to formation of 2-subtituted-
3-phenyl-4-(3H)-quinazolinones85.
(2) By the cyclization of 2-(3-phenylthiouredo)-benzoic acid with acetic anhy
dride to give 2-N-phenylamino-4H-3,1-benzothiazine-4-one followed by
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(3) By the condensation of 4-amino-5-mercapto-triazoles with benzoxazinones
led to formation of triazolylquinazolinones87.
(4) By the reaction of 2-amino-benzamine with oxazolone led to formation of
2-methyl-3-styryl-4-(3H)-quinazolinones88 .
(5) By the microwave induced dry media DDQ oxidation of 2-amino-benzamides/
benzhydroxamic acid led to formation of 2-aryl-quinazolin-4(3H)-ones89-90.
(6) By [4+2] cycloaddition reaction between 2,4-diphenylpyrimidine o-quino di-
methane and dimethyl acetylelenedicarboxylate leads to 2,4-diphenyl
quinazolin-6,7-dicarboxylate 91.
OTHER APPLICATION ASPECT :
Quinazoline is used as insect control agent known as Fenazaquin which
has following structure (33)
N
N




Literature survey undertaken for quinazolone derivatives are associated
with following diverse pharmacological  activities which  are as under.
(1) Anticonvulsant92 (2) H1-Antihistaminic activity
93
(3) Antimicrobial activity94-98,121 (4) Antiinflammatory and Analgesic99
(5) Antihypertensive100 (6) Tuberculostatic 101
(7) CNS-stimulant activity102 (8) Cardiovascular activity103
(9) Antiviral activity104 (10) Antidiabetics105
As quinazolones possess variety of biological activities, many quinazolone
derivatives are recently in clinical uses. Some important derivatives with their
uses are as under:
Methaqualone and Ethaqualone are used as sedative and hypnotic agents
where as Metolazone and Afloqualone are used as diuretic,antihypertensive and
muscle relaxant drugs.
(33)




































Choquette D. and Robert J.et al.,106 have prepared quinazolines(38)  and
reported that the compounds are inhibitors of protein kinases particularily GSK-
3(Glycogen Synthase Kinase-3) mammalian protein kinases.The invention also








T.Natalia,R.Kristina et al.,107 have reported the synthesis of
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Hennequin,L.F.Andre et al.,108  have prepared 4-anilinoquinazolines (41)
as antitumer agents.The compound useful as an anti-invasine agents in the con-
tainment and/or teatment of solid tumor disease. S.Chakravavarty et al.,109  pre-
pared quinazolines as TGF-b  and/or p38-a  kinase inhibitors. The com-



















S.M.Mossad et al., were prepared 6-Iodoquinazolines (44)  and screened
for antitubercular activity, the 4-alkylthio derivatives were found to be highly active.
Hwei-Ru Tsou et al.,111  have prepared 6-substituted-4-(3-bromophenylamino)
quinazolines(45) and tested for putative irreversible inhibitor of the Epidermal
Growth Factor Receptor (EGFR) and Human Epidermal Growth Receptor (HER-














Jeff B. Smaill et al.,112 have prepared 4-(phenylamino)quinazoline(46)
and tested for irreversible inhibition of the ATP binding site of the epidermal growth
factor receptor.Takashi Sohda et al.,113 have synthesised quinazoline deriva-
tives (47)  and tested for their anti-inflammatory effect.
(41) (42) (43)
(44) (45)











William A. Denny et al.,114 have prepared fused tricyclic quinazoline
analogues(48)  and tested for ATP site inhibitors of the tyrosine kinase activity of





L. F. henneduin et al.,115 have been prepared quinazoline(49) as










 J. Saravanan et al.,116 have prepared series of pyrazolo quinazolines











CH3 CH2 CO2 R'
Yang Zungyoon et al., have prepared quinazolone and have screened their
high cytotoxic activity against tumor cell in culture. Koko et al., have synthesised
quinazolone as partial estrogen agonists. M.M. Ghorab et al.,have been










Quinazolin-4-ones have received considerable attention in the literature of
pharmaceutical chemistry as potent and highly selective inhibitors of the tyrosine
kinase activity of the Epidermal Growth Factor receptor118-119 . J.Caroline et
al.,120   have been synthesised quinazolines prodrugs of thymidylate synthase















In pursuing the work on the systems incorporating pharmaceutically active
molecules, the new qunazolines derivatives have been synthesised which have
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SECTION - I : Preparation and biological evaluation of 5,5,7-
Trimethyl 4-(1’-N-phenyl-3’-arylpyrazol-4 ’-yl)-2-
hydroxy-3,4,5,6-tetrahydroquinazolines.
SECTION - II : Preparation and biological evaluation of 5,5,7-
Trimethyl-4-(1’-N-phenyl-3’-arylpyrazol- 4’-yl)-2-
mercapto-3,4,5,6-tetrahydroquinazolines.
SECTION - III :   Preparation and biological evaluation of 5,5,7-
Trimethyl-4-(1’-N-phenyl-3’-arylpyrazol-4’-yl)-2-
amino-3,4,5,6-tetrahydroquinazolines.
SECTION - IV : Preparation and biological evaluation of 4-Aryl-
5,5-dimethyl-7-(2-piperidin-1-yl-ethyl)-2-hydroxy-
3,4,5,6-tetrahydroquinazolines.
SECTION - V :    Preparation and  biological  evaluation 4- Aryl-5,5-
dimethyl-7-(2-piperidin-1-yl-ethyl)-2-mercapto-3,4,
5,6-tetrahydroquinazolines.
163163S t u d i e s  o n  q u i n a z o l i n e s
SECTION - I
Preparation and biological evaluation of 5,5,7-Trimethyl 4-(1’-
N-phenyl-3’-arylpyrazol-4’-yl)-2-hydroxy-3,4,5,6-tetrahydro
quinazolines.
Looking to the wide spectrum of biodynamic act iv i t ies 92-105  o f
quinazolines and in order to have highly potent  therapeutic agents, the synthesis
of 5,5,7-Trimethyl 4-(1’-N-phenyl-3’-aryl pyrazol-4’-yl)-2-hydroxy-3,4,5,6-tetrahydro
quinazolines (l1-8) have been undertaken by the cyclocondensation of 1-phenyl-








The constitution of the products (l1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (l1-8) were assayed for their in vitro biological assay like  an-
tibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(l1-8)                R=Aryl
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168168S t u d i e s  o n  q u i n a z o l i n e s
REACTION SCHEME



















169169S t u d i e s  o n  q u i n a z o l i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 5,5,7-TRIMETHYL-4-(1’-
N-PHENYL-3’-ARYLPYRAZOL-4’-YL)-2-HYDROXY-3,4,5,6-TETRAHYDRO
QUINAZOLINES.
(A) Preparation of 5,5,7-Trimethyl-4-(1’,3’-diphenylpyrazol-4’-yl)-2-hydroxy-
3,4,5,6-tetrahydroquinazoline (l1).
A mixture of 1,3-diphenyl-1H-pyrazole-4-carbaldehyde (2.48 gm, 0.01M),
3,5,5-trimethylcyclohex-2-en-1-one(1.38 ml, 0.01M) and urea(0.60 gm, 0.01M) was
reflux for 10 hrs. The reaction mixture was cooled at room temp. for 2 hrs. The
yellow crystlline product obtained was isolated and recrystallized from ethanol.
Yield : 52%, M.P. : 208°C, Rf1
 : 0.58, Rf2
 :0.62 (Required : C, 76.10%; H, 6.34%;
N, 13.66% for C 26H26N4O, Found : C, 76.04%; H, 6.30% ; N, 13.60%).
.
Similarly, other compounds (l1-8) were synthesized. The physical data are
recorded in Table No. 12.
(B) Antimicrobial activity of 5,5,7-Trimethyl-4-(1’-N-phenyl-3’-arylpyrazol-
4’-yl)-2-hydroxy-3,4,5,6-tetrahydroquinazoline s (l1-8).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
12a, 12b & 12c.
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174174Studies  on quInazolines
SECTION - II
Preparation and biological evaluation of 5,5,7-Trimethyl 4-(1’-
N-phenyl-3’-arylpyrazol-4 ’-yl)-2-mercapto-3,4,5,6-tetrahydro-
quinazolines.
Looking to the wide spectrum of biodynamic act iv i t ies 92-105  o f
quinazolines and in order to have highly potent therapeutic agents, the synthesis
of 5,5,7-Trimethyl 4-(1’-N-phenyl-3’-aryl pyrazol-4’-yl)-2-mercapto -3,4,5,6-tetrahydro-










The constitution of the products (m1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (m1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(m1-8)                R=Aryl
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176176Studies  on quInazolines
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179179Studies  on quInazolines
REACTION SCHEME



















180180Studies  on quInazolines
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 5,5,7-TRIMETHYL-4-(1’-
N-PHENYL -3’-ARYLPYRAZOL-4’-YL)-2-MERCAPTO-3,4,5,6-TETRAHYDRO-
QUINAZOLINES.
(A) Preparation of 5,5,7-Trimethyl-4-(1’,3’-diphenylpyrazol-4’-yl)-2-mercapto-
3,4,5,6-tetrahydroquinazoline (m1).
A mixture of 1,3-diphenyl-1H-pyrazole-4-carbaldehyde(2.48 gm, 0.01M),
3,5,5-trimethylcyclohex-2-en-1-one(1.38 ml, 0.01M) and thiourea(0.76 gm, 0.01M)
was reflux for 10 hrs. The reaction mixture was cooled at room temp. for 2 hrs. The
yellow crystlline product obtained was isolated and recrystallized from ethanol.
Yield : 55%, M.P. : 232°C, Rf1
 : 0.42, Rf2
 :0.45 (Required : C, 73.24%; H, 6.10%;
N, 13.15% for C 26H26N4S Found : C, 73.20%; H, 6.50% ; N, 13.10%).
.
Similarly, other compounds (m1-8) were synthesized. The physical data are
recorded in Table No. 13.
(B) Antimicrobial activity of 5,5,7-Trimethyl-4-(1’-N-phenyl-3’-arylpyrazol-
4’-yl)-2-mercapto-3,4,5,6-tetrahydroquinazoline s(m1-8).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
13a, 13b & 13c.





































































   





































































































   






































   






































   








































   








































   









































   






































   






































   




   

























































   
   
   
   
   
   
   


















   






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































185185S t u d i e s  o n  q u i n a z o l i n e s
SECTION - III
Preparation and biological evaluation of 5,5,7-Trimethyl-4-(1’-
N-phenyl-3’-arylpyrazol-4 ’-yl)-2-amino-3,4,5,6-tetrahydro-
quinazolines.
Looking to the wide spectrum of biodynamic act iv i t ies 91-105  o f
quinazolines and in order to have highly potent therapeutic agents, the synthesis
of 5,5,7-Trimethyl-4-(1’-N-phenyl-3’-aryl pyrazol-4’-yl)-2-amino-3,4,5,6-tetrahydro-










The constitution of the products (n1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (n1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(n1-8)                R=Aryl
186186S t u d i e s  o n  q u i n a z o l i n e s
IR SPECTRAL  STUDY OF  5,5,7-TRIMETHYL-4-(1’-N-PHENYL-3’-(p-METHOXY-
PHENYL)PYRAZOL-4’-YL)-2-AMINO-3,4,5,6-TETRAHYDROQUINAZOLINE (n8).














 C=C + C=N and ring
 skeletal  vibration
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C=N  str.
 N -N  def.
 C -N str.
 C-O-C str. (asym.)







































































   2925.8
   2854.5
   1442.7
   1346.2
   1512.1
   1541.1
   3082.0
   1114.8
     810.0
1623.9
    1651.0
    1215.1
1247.9
   1078.1
    3408.0
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m/z = 368(M+2) m/z = 352(M
















190190S t u d i e s  o n  q u i n a z o l i n e s
REACTION SCHEME



















19191S t u d i e s  o n  q u i n a z o l i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 5,5,7-TRIMETHYL-4-(1’-
N-PHENYL-3’-ARYLPYRAZOL-4’-YL)-2-AMINO-3,4,5,6-TETRAHYDRO-
QUINAZOLINES.
(A) Preparation of 5,5,7-Trimethyl-4-(1’,3’-diphenylpyrazol-4’-yl)-2-amino-
3,4,5,6-tetrahydroquinazoline(n1).
A mixture of 1,3-diphenyl-1H-pyrazole-4-carbaldehyde(2.48 gm,0.01M),
3,5,5-trimethylcyclohex-2-en-1-one (1.38 gm, 0.01M) and guanidine hydrochlo-
ride(1.0 gm, 0.01M) was reflux for 10 hrs. The reaction mixture was cooled at room
temp. for 2 hrs. The yellow crystlline product obtained was isolated and recrystal-
lized from ethanol. Yield : 56%, M.P. : 218°C, Rf1
 : 0.48, Rf2
 :0.51 (Required : C,
76.28%; H, 6.60%; N, 17.11% for C 26H27N5, Found : C, 76.25%; H, 6.55% ; N,
17.06%).
.
Similarly, other compounds  (n1-8) were synthesized. The physical data are
recorded in Table No. 14.
(B) Antimicrobial activity of 5,5,7-Trimethyl-4-(1’-N-phenyl-3’-arylpyrazol-
4’-yl)-2-amino-3,4,5,6-tetrahydroquinazoline s(n1-8).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
14a, 14b & 14c.

































































   
   



































































































   





































   





































   







































   







































   








































   





































   






































   
   





   

























































   
   
   
   
   
   
   


















   












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































196196S t u d i e s  o n  q u i n a z o l i n e s
SECTION - IV
Preparation and biological evaluation of 4-Aryl-5,5-
dimethyl-7-(2’-piperidin-1’-yl-ethyl)-2-hydroxy-3,4,5,6-tetrahydro-
quinazolines.
Looking to the wide spectum of  b iodynamic act iv i t ies 91-105  o f
quinazolines and in order to have highly potent therapeutic agents, the synthesis
of 4-Aryl-5,5-dimethyl-7-(2’-piperidin-1’-yl-ethyl)-2-hydroxy-3,4,5,6-tetrahydro-
quinazolines (o1-10) have been undertaken by the condensation of 4-aryl-2-hydroxy-
5,5,7-trimethyl-3,4,5,6-tetrahydroquinazolines, piperidine and formaldehyde in  presence







The constitution of the products (o1-10) have been delineated by elemen-
tal analyses, IR, PMR  and Mass spectral data.
The products (o1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(o1-10)                R=Aryl












































































































198198S t u d i e s  o n  q u i n a z o l i n e s
PMR SPECTRAL STUDY OF 4-(p-METHOXYPHENYL)-5,5-DIMETHYL-7-(2’-

























































































































































































   




















m/z = 365 (m+1)
m/z = 349 (m-1)
NH
NN
m/z = 321 (m+1)
CH2
NN
m/z = 306 (m+1)
NH2N
m/z = 294 (m+1)
N
m/z = 279 (m+2)
m/z = 189 (m-1)
N















m/z = 108 (m-1)
m/z = 82 (m-1)
(o10)
201201S t u d i e s  o n  q u i n a z o l i n e s
REACTION SCHEME


























20202S t u d i e s  o n  q u i n a z o l i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 4-ARYL-5,5-DIMETHYL-
7- (2 ’ -PIPERIDIN-1’ -YL-ETHYL)-2-HYDROXY-3,4,5 ,6-TETRAHYDRO-
QUINAZOLINES.
(A) Preparation of 4-(p-methoxyphenyl)-2-hydroxy 5,5,7-trimethyl-3,4,5,6-
tetrahydroquinazoline (II10).
A mixture of 3,5,5-trimethylcyclohex-2-en-1-one(1.38ml,0.01M ) , p-methoxy
benzaldehyde(1.36ml,0.01M) and urea(0.60gm, 0.01M) was refluxed for 10 hrs.
The reaction mixture was poured into ice cold water. The product obtained was
filtered, dried and recrystallized from ethanol. Yield : 62%, M.P. : 182°C, Rf1
 :
0.52, Rf2
 :0.56 (Required : C, 72.48%; H, 7.38%; N, 9.40% for C24H33N3O2,
Found : C, 72.46%; H, 7.35% ; N, 9.37%).
Similarly, other compounds  (II1-10) were synthesized. The physical data are
recorded in Table No. II.
(B) Preparation of 4-(p-methoxyphenyl)-5,5-dimethyl-7-(2’-piperidin-1’-yl-
ethyl)-2-hydroxy-3,4,5,6-tetrahydroquinazoline (o10).
A mixture of 4-(p-methoxyphenyl)-2-hydroxy 5,5,7-trimethyl-3,4,5,6-tetrahydro-
quinazolines(2.98gm, 0.01M), piperidine(0.85ml, 0.01M), paraformaldehyde and
con.HCl (2.0ml)was refluxed for 6 hrs. The reaction mixture was poured into ice
cold water. The product obtained was filtered, dried and recrystallized from
ethanol.Yield : 56%, M.P. : 185°C, Rf1
 : 0.58, Rf2
 :0.62 (Required : C, 72.91%; H,
8.35%; N, 10.63% for C 24H33N3O2, Found : C, 72.84%; H, 8.31% ; N, 10.58%).
Similarly, other compounds  (o1-10) were synthesized. The physical data are
recorded in Table No. 15.
(C) Antimicrobial activity of 4-Aryl-5,5-dimethyl-7-(2’-piperidin-1’-yl-
ethyl)-2-hydroxy-3,4,5,6-tetrahydroquinazolines (o 1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
15a, 15b & 15c.










































































   

















































































   






































   







































   








































   








































   






































   







































   





































   




   








































   










































   















































   
   
   
   
   
   
   


















   






































































































   
   
   
   



































































































   






































   







































   








































   








































   






































   







































   





































   




   








































   










































   















































   
   
   
   
   
   
   


















   























































   
   
   
   




























































   
   
   
   













   
   
   
   
   
   
   
   
   
   
   
   
   
   
   













5 - - - - - - - - - -
10 - - - - - - - - - -
25 11 12 10 10 12 11 10 11 10 12
50 12 12 10 11 12 11 10 12 10 12
10
0
13 13 12 13 13 13 12 12 12 12
25
0
13 14 12 13 14 13 13 13 13 14
50
0
14 14 13 14 14 14 14 14 13 14
5 - - - - - - - - - -
10 - - - - - - - - - -
25 12 14 11 12 13 12 11 13 12 13
50 13 14 12 12 13 13 11 13 12 14
10
0
13 15 14 14 14 15 13 14 14 14
25
0
14 16 14 14 15 15 13 15 15 15
50
0












































































































































   












































11 10 16 18
14 13 19 19
16 19 21 20
18 20 21 21
19 20 22 21
20 22 22 23
10 12 17 19
13 14 19 22
14 19 21 25
16 20 22 26
18 21 22 28
21 22 23 28
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5 - - - - - - - - - -
10 - - - - - - - - - -
25 14 15 13 13 15 14 13 14 14 15
50 15 16 13 14 16 14 14 15 15 15
10
0
17 17 15 16 16 15 15 15 16 16
25
0
17 17 16 17 17 16 16 17 16 17
50
0
18 18 16 17 17 18 17 18 17 17
5 - - - - - - - - - -
10 - - - - - - - - - -
25 15 16 15 15 16 15 14 16 15 16
50 17 17 16 15 17 16 15 17 15 16
10
0
19 19 16 17 17 16 15 18 15 17
25
0
19 19 17 18 18 18 17 18 17 17
50
0












































































































































   












































14 14 20 22
15 17 23 25
16 23 28 26
19 23 28 27
20 23 28 29
22 23 28 29
12 12 16 19
18 16 19 22
19 19 22 23
20 22 22 24
21 23 23 25
23 23 23 28




























































































   






























































o 2 o 5 o 1
0
o 2 o 5
o 2 o 5 o 8 o 1
0



























   
   
   
   




























































   
   
   
   
   













   
   
   
   
   
   
   
   
   
   
   
   
   
   











5 - - - - - - - - - -
10 - - - - - - - - - -
25 17 18 16 17 18 17 17 18 17 18
50 18 18 17 18 18 18 17 18 18 18
10
0
20 20 18 19 19 19 19 19 19 19
25
0
21 20 19 20 20 20 20 20 20 20
50
0
22 21 20 20 21 21 20 20 21 20
5 - - - - - - - - - -
10 - - - - - - - - - -
25 18 19 18 19 19 19 18 19 18 19
50 19 19 18 19 20 19 19 19 19 19
10
0
21 20 20 21 20 20 20 21 20 21
25
0
22 22 20 22 21 22 22 21 22 21
50
0











































































































































   



















































































































   






























































208208S t u d i e s  o n  q u i n a z o l i n e s
SECTION - V
Preparation and biological evaluation of 4-Aryl-5,5-
dimethyl-7-(2’-piperidin-1’-yl-ethyl)-2-mercapto-3,4,5,6-tetrahydro-
quinazolines.
Looking to the wide spectrum of  biodynamic act iv i t ies 91-105  o f
quinazolines and in order to have highly potent therapeutic agents, the synthesis
of 4-Aryl-5,5-dimethyl-7-(2’-piperidin-1’-yl-ethyl)-2-hydroxy-3,4,5,6-tetrahydro-
quinazolines (p1-10) have been undertaken by the condensation of 4-aryl-2-mercapto
5,5,7-trimethyl-3,4,5,6-tetrahydroquinazolines, piperidine and formaldehyde in presence







The constitution of the products (p1-10) have been delineated by elemen-
tal analyses, IR, PMR and Mass spectral data.
The products (p1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
(p1-10)                R=Aryl













































































































210210S t u d i e s  o n  q u i n a z o l i n e s

















































































































































































































m/z = 77 








213213S t u d i e s  o n  q u i n a z o l i n e s
REACTION SCHEME


























214214S t u d i e s  o n  q u i n a z o l i n e s
EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 4-ARYL-5,5-DIMETHYL-
7-(2’-PIPERIDIN-1’-YL-ETHYL)-2-MERCAPTO-3,4,5,6-TETRAHYDRO-
QUINAZOLINES.
(A) Preparation of 4-(p-methoxyphenyl)-2-mercapto-5,5,7-trimethyl-3,4,5,6-
tetrahydroquinazoline.
A mixture of 3,5,5-trimethylcyclohex-2-en-1-one(1.38ml, 0.01M), p-methoxy
benzaldehyde(1.36ml, 0.01M)) and thiourea(0.76gm, 0.01M)) was refluxed for 10
hrs. The reaction mixture was poured into ice cold water. The product obtained
was filtered, dried and recrystallized from ethanol. Yield : 65%, M.P. : 168°C.
(B) Preparation of 4-(p-methoxyphenyl)-5,5-dimethyl-7-(2’-piperidin-1’-yl-
ethyl)-2-mercapto-3,4,5,6-tetrahydroquinazoline (p10).
A mixture of 4-(p-methoxyphenyl) -2-mercapto-5,5,7-trimethyl-3,4,5,6-
tetrahydroquinazolines (3.14gm, 0.01M)), piperidine (0.85ml, 0.01M)), paraformalde-
hyde and con.HCl (2.0ml)was refluxed for 6 hrs. The reaction mixture was poured
into ice cold water. The product obtained was filtered, dried and recrystallized
from ethanol. Yield : 68%, M.P. : 180°C, R f1
 : 0.58, R f2
 :0.62 (Required : C, 70.07%;
H, 8.03%; N, 10.22% for C24H33N4OS, Found : C, 70.03%; H, 7.99% ; N,
10.17%).
Similarly, other compounds (p1-8) were synthesized. The physical data are
recorded in Table No. 16.
(C) Antimicrobial activity of 4-Aryl-5,5-dimethyl-7-(2’-piperidin-1’-yl-
ethyl)-2-mercapto-3,4,5,6-tetrahydroquinazolines(p 1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
16a, 16b & 16c.
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The pyrazoline ring system consists of a two adjacent nitrogen atoms on 1
and 2 positions with one double bond in a five membered heterocyclic ring.
Pyrazoline is also known as dihydropyrazole. The chemistry of pyrazolines is par-
allel to that of pyrazoles hence they are treated as sub-units of pyrazoles.
Pyrazoline has three possible tautomeric structures, but the structure (52) shown








The chemistry of pyrazoline was reviewed by Jarnoe in 1967. Different meth-
ods are available in literature for the preparation of 2-pyrazolines.
METHODS FOR SYNTHESIS OF PYRAZOLINES :
Extensive studies have been made in the field of synthesis of pyrazoline. Vari-
ous methods for the synthesis of pyrazoline have been descri bed as under:
(1) By the reaction of a ,b -unsaturated carbonyl compounds with an aliphatic
or aromatic  hydrazine hydrate 122 .
(2) By the reaction of hydrazine hydrate with cinnamaldehyde123 .
(3) By the reaction of 3-methyl-4-benzyl derivatives with benzyl chloride in the
presence of sodium metal  furnish to a compound which on reduction by
sodium metal affords 1-phenyl-5-hydroxypyrazolines124 .
(4) By the reaction of a,b -ethylenic ketone with excess of hydrazine hydrate 125.
(5) By the reaction of N ’-phenylbenzenecarboximidohydrazide with unsaturated
ketones126 .
(6) By the reaction of benzalazide with b -propiolactone led to the formation of
1-benzyl-3-phenyl-2-pyrazolines127 .
(52)
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OTHER APPLICATION ASPECT :
H. Jamin et al.,128  have prepared compound (53) which finds utility as
100ppm foliar or bait applications gave 70-100% kill of Spodoptera eridaria,













M.Kenji, et al.,129  have prepared compound (54) which showed










2-Pyrazoline derivatives are associated with diverse biological activities viz.,
(a) Anticancer130 (b) Antitumor131
(c) Antipyretic activity132 (d) Antiallergic133,148
(e) Local anaesthetic activity134 (f) Antiasthmatic 135,148
(g) Antimicrobial activity136,149 (h) Antiviral137
(i) Antidiabetic activity138 (j) Tranquilizing activity139
(k) Fungicidal activity140 (l) Insecticidal activity141
(m) Hypoglycemic activity142 (n) Diuretic activity143
(o) Anticonvulsant activity144 (p) Analgesic activity145
(q) Cardiovascular activity146 (r) Antibacterial147
(s) Antiinflammatory148,149 (t) Antihypertensive150
(53)
(54)
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I.M.Abdou et al.,151  have prepared 1,2-Dihydropyrazole glucosides
and tested for their antitumor activity. Gucoside (55)  shows an in vitro IC50 value














Ki-Jun Hwang et al.,152 have synthesised compound (56) which












Akio Ejima et al.,153 have prepared 3-[4-(3-chlorophenyl)-1-
piperazinyl]-1-[5-methyl-1-(2-pyrimidinyl)-4-pyrazolyl]-1-trans-propane (57)
and evaluated by assays of growth inhibition against several tumor cell lines in
vitro as well as antitumor activity against some tumor models when dosed both









Kim Dal-Kee, Lee Ju young et al.,154  have prepared compound (58)
and evaluated for their biological activity, which showed the highest Phospho-
diesterage type-5 (PDE 5) inhibitory activity and comparable to better selectivity














M.M.F.Ismail et al.,155  have prepared [1-(2,3,4,9-tetrahydrocarba-
zol-1-yl)-2-phenyl-1-[(3-methyl-1-phenyl)pyrazol-5-one-1-ylidine]ethane










S.H.D.Hollis et al.,156  have prepared compound (60) and shows that
the compounds are essentially devoid of activity against in vintro L1210 Leuke-





R.Soliman157  were prepared four series of p-[3,5-dimethyl-(and
5-methyl-3-carboxy-)pyrazole-1]benzenesulfonylureas (61) / thioureas (62)
/ 2-thiohydantions (63) and 5,6-dihydro-4(3H)-oxo-2(1H)-pyrimidinones (64)
for evaluation as hypoglycemic agents. Biological testing of these compouds































In pursuing the work on the systems incorporating pharmaceutically active
molecules, the new pyrazolines derivatives have been synthesised which have
been described as under:
SECTION - I: Preparation and biological evaluation of 3-Methyl-
5-N-aroyl-7-aminopyrazolo[3’,4’:4,5]thieno[2,3-c]-
pyrazoles.
SECTION - II: Preparation and biological evaluation of 3-Methyl-
6-aryl-1,5,6,7-tetrahydropyrazolo [3’,4’:4,5]thieno-
[2,3-d]pyrimidin-8-ones.
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SECTION - I
Preparation and biological evaluation of 3-Methyl-5-N-aroyl-
7-aminopyrazolo[3’,4’:4,5]thieno[2,3-c]pyrazoles.
Looking to the biodynamic activities130-150  and the other  properties 128-
129  of pyrazoles and in order to have highly potent therapeutic agents, the syn-
thesis of 3-Methyl-5-N-aroyl-7-aminopyrazolo[3’,4’:4,5]thieno[2,3-c]pyrazoles
(q1-10) have been undertaken by  the condensation of 3-methyl-5-amino-6-cyano-











The constitution of the products (q1-8) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (q1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
   (q1-8)                R=Aryl
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         Type             Vibration Mode             Frequency in cm-1                   Ref.
          Observed       Reported
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-5-N-AROYL-
7-AMINOPYRAZOLO[3’,4’:4,5]THIENO[2,3-c]PYRAZOLES.
(A) Preparation of (5-methyl-2,4-dihydro-3H-pyrazol-3-ylidene)malononitrile.
A mixture of 5-methyl-2,4-dihydro-3H-pyrazol-3-one(0.98gm),malononitrile(0.66ml)
and piperidyle acetate(2-3 drops) was refluxed for 6 hrs. The reaction mixture was
poured into ice cold water. The product obtained was filtered, dried and recrys-
tallized from ethanol. Yield : 52%, M.P. : 192°C, R f1
 : 0.45, R f2
 :0.52 (Required : C,
57.53%; H, 4.11%; N, 38.36% for C7H6N4, Found : C, 57.50%; H, 4.07% ; N,
38.31%).
(B) Preparation of 3-methyl-5-amino-6-cyano-1H-thieno[3,2-c]pyrazole.
A mixture of (5-methyl-2,4-dihydro-3H-pyrazol-3-ylidene)malononitrile(1.46gm),
sulfer powder(0.32gm) and morpholine(0.87ml)  was refluxed for 6 hrs. The reac-
tion mixture was poured into ice cold water. The product obtained was filtered,
dried and recrystallized from ethanol. Yield : 58%, M.P. : 206°C, Rf1
 : 0.48, Rf2
:0.52 (Required : C, 47.19%; H, 3.37%; N, 31.46% for C7H6N4S, Found : C,
47.12%; H, 3.33% ; N, 31.42%).
(C) Preparation of 3-Methyl-5-N-(4-methoxybenzoyl)-7-aminopyrazolo-
[3’,4’:4,5]thieno[2,3-c]pyrazole (q 10).
A mixture of  3-methyl-5-amino-6-cyano-1H-thieno[3,2-c]pyrazole(1.78 gm,
0.01M), 4-methoxybenzohydrazide(1.66gm, 0.01M),and gla. aceticacid(20ml) was
reflux for 6 hrs. The reaction mixture was poured into ice cold water. The product
obtained was filtered, dried and recrystallized from ethanol. Yield : 52%, M.P. :
310°C, Rf1
 : 0.52, Rf2
 :0.54 (Required : C, 55.05%; H, 3.97%; N, 21.41% for
C15H13N5O2S, Found : C, 55.01%; H, 3.92% ; N, 21.37%).
Similarly, other compounds (q1-10) were synthesized. The physical data are
recorded in Table No. 17.
(D) Antimicrobial activity of 3-Methyl-5-N-aroyl-7-aminopyrazol[3’,4’:4,5]
thieno[2,3-c]pyrazoles(q1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35.The MIC values of test solution are recorded in Table No.
17a, 17b & 17c.
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SECTION - II
Preparation and biological evaluation of 3- Methyl-6-aryl-
1,5,6,7-tetrahydropyrazolo [3’,4’:4,5]thieno[2,3-d]pyrimidin-8-ones.
Looking to the biodynamic activities130-150   and the other properties128-
129  of pyrazoles and in order to have highly potent therapeutic agents, the syn-
thesis of 3 -Methyl-6-aryl-1,5,6,7-tetrahydropyrazolo [3’,4’:4,5]thieno[2,3-d]-
pyrimidin-8-ones (r1-10) have been undertaken by the cyclocondensation of
3-methyl -5-amino-6-carboxamido -1H-thieno[3,2-c]pyrazole and  different substituted











The constitution of the products (r1-10) have been delineated by elemental
analyses, IR, PMR and  Mass spectral data.
The products (r1-10) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
   (r1-10)                R=Aryl
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 C=C + C=N and ring
 skeletal vib.
 C-H str.
 C-H i.p. def.
 C-H o.o.p. def.
 C-S-C str.
 C=O
 C-O-C str. (asym.)
 C-O-C str. (sym.)
 N-H str.
 N-H def.
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m/z = 179(M-1) m/z = 193(M+1)
(r10)
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3-METHYL-6-ARYL-
1,5,6,7-TETRAHYDR OPYRAZOL O[3’,4’:4,5]THIENO[2,3-d ]PYRIMIDIN-8-
ONES.
(A) Preparation of (5-methyl-2,4-dihydro-3H-pyrazol-3-ylidene)malononitrile.
For preparation, See part-3,Section-1,Page no.232
(B) Preparation of 5-amino-3-methyl-1H-thieno[3,2-c]pyrazole-6-carbonitrile.
For preparation, See part-3,Section-1,Page no.232
(C) Preparation of 3-Methyl-6-(p-methoxyphenyl)-1,5,6,7- tetrahydropyrazolo-
[3’,4’:4,5]thieno[2,3-d]pyrimidin-8-one (r10).
A mixture of 3-methyl-5-amino-6-carboxamido-1H-thieno[3,2-c]pyrazole
(1.96 gm, 0.01M), 4-methoxybenzaldehyde(1.36gm, 0.01M) and gla. aceticacid
(20ml) was reflux for 6 hrs. The reaction mixture was poured into ice cold water.
The product obtained was filtered, dried and recrystallized from ethanol. Yield :
55%, M.P. : 210°C, Rf1
 : 0.60, Rf2
 :0.63 (Required : C, 57.32%; H, 4.46%; N,
17.83% for C15H14N4O2S, Found : C, 57.27%; H, 4.41% ; N, 17.77%).
Similarly, other compounds (r1-10) were synthesized. The physical data are
recorded in Table No. 18.
(D) Antimicrobial activity of 3-Methyl-6-aryl-1,5,6,7-tetrahydropyrazolo-
[3’,4’:4,5]thieno[2,3-d]pyrimidin-8-ones(r1-10).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35. The MIC values of test solution are recorded in Table No.
18a, 18b & 18c.
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SECTION - III
Preparation and biological evaluation of 3,6-Dimethyl-6-
aryl-1,5,6,7-tetrahydro-1H-pyrazolo[3’ ,4’ :4,5]thieno[2,3-
d]pyrimidin-8-ones.
Looking to the biodynamic activities130-150  and the other properties128-
129  of pyrazoles and in order to have highly potent therapeutic agents, the syn-
thesis of 3 ,6 - d imethy l-6-aryl-1,5,6,7- te t rahydro -1H-pyrazo lo [3’ ,4 ’ :4,5]
thieno[2,3-d]pyrimidin-8-ones (s1-8) have been undertaken by the cycloconden-
sation of 3-methyl-5-amino-6-carboxamido-1H-thieno[3,2-c]pyrazole and different sub-
stituted aromatic acetophenone in the presence of con.sulfuric acid and gla. acetic
acid.
The constitution of the products (s1-10) have been delineated by elemental
analyses, IR, PMR  and Mass spectral data.
The products (s1-8) were assayed for their in vitro biological assay like
antibacterial activity towards S. pyogens MTCC-442 and S. aureus MTCC-96
(Gram positive) and E. coli MTCC-443 and B. subtillis MTCC-441 (Gram
negative) bacterial strain and antifungal activity towards Aspergillus niger
MTCC-282  and Candida albicans MTCC-227 at different concentrations
(µg/ml) : 0 (control), 5, 10, 25, 50, 100, 200, 500 for their MIC  (Minimum Inhibi-
tory  Concentration) values. The biological activities of the synthesized com-
pounds were compared with standard drugs.
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PMR SPECTRAL STUDY OF 3,6-DIMETHYL-6-(p-METHOXYPHENYL)-1,5,6,7-
TETRAHYDRO-1H-PYRAZOLO[3’,4’:4,5]THIENO[2,3-d]PYRIMIDIN-8-ONE (s10).
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REACTION SCHEME
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EXPERIMENTAL
PREPARATION AND BIOLOGICAL EVALUATION OF 3,6-DIMETHYL-6-ARYL-
1,5,6,7-DIHYDRO-1H-PYRAZOLO[3’,4’:4,5]THIENO[2,3-d ]PYRIMIDIN-8-
ONES.
(A) Preparation of (5-methyl-2,4-dihydro-3H-pyrazol-3-ylidene)malononitrile.
For preparation, See part-3,Section-1,Page no.232
(B) Preparation of 5-amino-3-methyl-1H-thieno[3,2-c]pyrazole-6-carbonitrile.
For preparation, See part-3,Section-1,Page no.232
(C) Preparation of 3,6-Dimethyl-6-(p-methoxyphenyl)-1,5,6,7-dihydro-1H-pyrazolo-
[3’,4’:4,5]thieno[2,3-d]pyrimidin-8-one (s8).
A mixture of 3-methyl-5-amino-6-carboxamido-1H-thieno[3,2-c]
pyrazole(1.98 gm, 0.01M), 4-methoxyacetophenone(1.50gm, 0.01M),con.H2SO4
and gla. CH3COOH (20ml) was refluxed for 6 hrs. The reaction mixture was poured
into ice cold water. The product obtained was filtered, dried and recrystallized
from ethanol. Yield : 50%, M.P. : 318°C, R f1
 : 0.55, R f2
 :0.58 (Required : C, 58.54%;
H, 4.88%; N, 17.10% for C16H16N4O2S, Found : C, 58.50%; H, 4.83% ; N,
17.05%).
Similarly, other compounds (s1-8) were synthesized. The physical data are
recorded in Table No. 19.
(D) Antimicrobial activity of 3,6-Dimethyl-6-aryl-1,5,6,7-dihydro-1H-pyrazolo-
[3’,4’:4,5]thieno[2,3-d]pyrimidin-8-ones (s1-8).
Antimicrobial activity testing was carried out as described in part-1,
section-I, page No. 35.The MIC values of test solution are recorded in Table No.
19a, 19b & 19c.
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